PART I
Forward-Looking Statements
This report contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995,
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements relate to
current expectations, beliefs, projections and similar expressions concerning matters that are not historical facts. Words such as "project," "believe," "anticipate," "plan," "expect," "intend,"
"may," "should," "will," "would," and similar words and expressions are intended to identify forward-looking statements. The expectations, beliefs, projections and similar expressions reflected in the
forward-looking statements may prove to be inaccurate, and actual results may differ materially from those reflected in such forward-looking statements. Important factors that could cause our actual
results to differ materially from those expectations are disclosed in this report, including, without limitation, those described in Part I, Item 1, "Business," Part I,
Item 1A, "Risk Factors" and Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" as well as elsewhere in this report and other
documents filed by us from time to time with the Securities and Exchange Commission. Such factors, of course, do not include all factors that might affect our business and financial condition.
Although we believe that the assumptions upon which our forward-looking statements are based are reasonable, such assumptions could prove to be inaccurate and actual results could differ materially
from those expressed in or implied by the forward-looking statements. For example, we could be exposed to a variety of negative consequences as a result of delays related to the award of domestic and
international contracts; delays in customer programs; delays in revenue recognition related to the timing of customer acceptance; unanticipated impacts of sequestration and other U.S. Government
budget control provisions; changes in domestic and foreign government spending, budgetary, procurement and trade policies adverse to our businesses; global economic uncertainty; impact of volatility
in oil prices; unfavorable currency exchange rate fluctuations; market acceptance of our new and existing technologies, products and services; our ability to win new business and convert any orders
received to sales within the fiscal year in accordance with our operating plan; enforcement actions in respect of any noncompliance with laws and regulations including export control and environmental
regulations and the matters that are the subject of some or all of our ongoing investigations and compliance reviews, contract and regulatory compliance matters, and actions, if brought, resulting in
judgments, settlements, fines, injunctions, debarment or penalties; risks related to our pending acquisition of American Science and Engineering, Inc. ("AS&E") as well as other risks and
uncertainties, including but not limited to those detailed herein and from time to time in our Securities and Exchange Commission filings, which could have a material and adverse impact on our
business, financial condition and results of operation. All forward-looking statements contained in this report are qualified in their entirety by this statement. Moreover, we operate in a very
competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our
business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of
these risks, uncertainties and assumptions, the future events and trends discussed in this Annual Report on Form 10-K may not occur and actual results could differ materially and adversely from
those anticipated or implied in the forward-looking statements. We undertake no obligation other than as may be required under securities laws to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
ITEM 1. BUSINESS
General
OSI Systems, Inc., together with its subsidiaries, is a vertically integrated designer and manufacturer of specialized
electronic systems and components for critical applications. We sell our products and provide related services in diversified markets, including homeland security, healthcare, defense and aerospace.
Our company was originally incorporated in 1987 in California. In March 2010, we reincorporated our company in the State of Delaware. Our principal office is located at 12525 Chadron Avenue,
Hawthorne, California 90250.
1
Table of Contents
We
have three operating divisions: (a) Security, providing security and inspection systems, turnkey security screening solutions and related services; (b) Healthcare,
providing patient monitoring, diagnostic cardiology, anesthesia delivery and ventilation systems and defibrillators; and (c) Optoelectronics and Manufacturing, providing specialized electronic
components and electronic manufacturing services for the Security and Healthcare divisions, as well as to external original equipment manufacturer ("OEM") customers and end users for applications in
the defense, aerospace, medical and industrial markets, among others.
Through
our Security division, we provide security screening products, and services worldwide under the "Rapiscan Systems" trade name. Rapiscan Systems products fall into the following
categories: baggage and parcel inspection; cargo and vehicle inspection; hold (checked) baggage screening; people screening; radiation detection; and explosive and narcotics trace detection. In
addition to these products, we provide site design, installation, training and technical support services to our customers. We also provide turnkey security screening solutions under the "S2" trade
name, which can include the construction, staffing and long-term operation of security screening checkpoints, including ports and borders, for our customers.
Through
our Healthcare division, we design, manufacture, market and service patient monitoring, diagnostic cardiology, anesthesia delivery and ventilation systems and defibrillators
globally to end users under the "Spacelabs" and "Primedic" trade names, and related supplies and accessories under the names "Spacelabs"
and "Statcorp Medical." These products are used by care providers in critical care, emergency and perioperative areas within hospitals as well as physicians' offices, medical clinics and ambulatory
surgery centers; our defibrillators are also used in public facilities.
Through
our Optoelectronics and Manufacturing division, we design, manufacture and market optoelectronic devices and provide electronics manufacturing services globally for use in a
broad range of applications, including aerospace and defense electronics, security and inspection systems, medical imaging and diagnostics, telecommunications, office automation, computer peripherals,
industrial automation systems, automotive diagnostic systems, gaming systems and consumer products. We sell our optoelectronic devices primarily under the "OSI Optoelectronics" trade name and perform
our electronics manufacturing services primarily under the "OSI Electronics," "APlus Products," "Altaflex," "Briton EMS" and "Union Four" trade names. We provide our optoelectronic devices and
electronics manufacturing services to OEM customers and end users, as well as to our own Security and Healthcare divisions.
In
fiscal 2016, revenues from the Security division were $411.2 million, or approximately 50% of our revenues; revenues from the Healthcare division amounted to
$211.5 million, or approximately 25% of our revenues; and third-party revenues from the Optoelectronics and Manufacturing division were $207.0 million, or approximately 25% of our
revenues. See note 13 to the consolidated financial statements for additional financial information concerning reporting segments and geographic areas.
Recent Developments
Pending Acquisition of AS&E.
On June 20, 2016, we and AS&E signed a definitive agreement pursuant to which we will
acquire AS&E for $37.00 in
cash per share of common stock of AS&E. The total purchase price is approximately $269 million, and we intend to fund the transaction with a combination of AS&E's cash on hand and money
borrowed under our revolving credit facility. As of June 30, 2016, AS&E reported cash and cash equivalents of $74 million. We believe this is a good strategic fit for the Company
consistent with our expansion strategy. The completion of the transaction is subject to the satisfaction of customary conditions, including, among others: (i) the requisite approval of AS&E's
shareholders, (ii) the expiration or termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR Act") and (iii) the absence of any
order or injunction issued by any court or governmental authority in the United States preventing the consummation of the transaction. We expect the transaction to close by December 31, 2016.
2
Table of Contents
For
more information regarding the pending acquisition of AS&E and the risks and uncertainties associated therewith, see "Item 1A. Risk Factors," "Item 7. Management's
Discussion and Analysis of Financial Condition and Results of Operations," and note 1 to our consolidated financial statements included within this Annual Report on Form 10-K.
Industry Overview
We sell our security and inspection systems and patient monitoring, cardiology and anesthesia systems primarily to end-users, while we
design and manufacture our optoelectronic devices and value-added subsystems, and provide electronics manufacturing services primarily for OEM customers.
Security.
A variety of technologies are currently used globally in security and inspection applications, including transmission
and backscatter
X-ray, 3-D and computed tomography, nuclear radiation detection, magnetometry, radar and trace detection. We believe that the market for security and inspection products will continue to be affected
by the threat of terrorist incidents and by new government mandates and appropriations for security and inspection products in the United States and internationally.
As
a result of the September 11, 2001 terrorist attacks on the World Trade Center and subsequent attacks in other locations worldwide, security and inspection products have
increasingly been used at a wide range of facilities other than airports, such as border crossings, railways, seaports, cruise line terminals, freight forwarding operations, sporting venues,
government and military installations and nuclear facilities. Congress passed the Aviation and Transportation Security Act and integrated many U.S. security-related agencies, including the U.S.
Transportation Security Administration, into the U.S. Department of Homeland Security. Under its directive from Congress, the U.S. Department of Homeland Security has since undertaken numerous
initiatives to prevent terrorists from entering the country, hijacking airliners, and obtaining and trafficking in weapons of mass destruction and their components, to secure sensitive U.S.
technologies and to identify and screen high-risk cargo before it is loaded onto airlines and ships, among others. These initiatives, known, for example, as the Customs-Trade Partnership Against
Terrorism, the U.S. Transportation Security Administration's Air Cargo Screening Mandate and the U.S. Customs and Border Protection Container Security Initiative, have resulted in an increased demand
for security and inspection products.
Certain
of the government sponsored initiatives in the United States, such as the U.S. Customs and Border Protection Container Security Initiative, the Customs-Trade Partnership Against
Terrorism and the U.S. Transportation Security Administration's Air Cargo Screening Mandate have also stimulated security programs in other areas of the world because the U.S. initiatives call on
other nations to bolster their port security strategies, including acquiring or improving their security and inspection equipment and screening operations. The international market for non-intrusive
inspection equipment and related services, therefore, continues to expand as countries that ship goods directly to the United States participate in such programs and as they choose to procure and
operate equipment in order to secure their own borders, transportation networks, facilities and other venues.
Congress
also passed legislation that calls for the inspection of international maritime cargo destined for the United States, domestic civil aviation cargo, and radiological and nuclear
threats in cargo entering the United States. Certain of our cargo and vehicle inspection systems are already being used internationally and by the U.S. Government to comply with these standards.
Following
recommendations outlined in "The 9/11 Commission Report," issued by the National Commission on Terrorist Attacks Upon the United States, the U.S. Department of Homeland
Security now requires the screening of all cargo carried on passenger airlines in the United States. Several of our hold (checked) baggage and cargo screening systems have been approved by the U.S.
Department of Homeland Security for this purpose and are being procured and used by freight forwarders, airlines, transportation companies and other businesses to fulfill their compliance
requirements.
3
Table of Contents
Furthermore,
the U.S. Department of Homeland Security's Science and Technology Directorate and Domestic Nuclear Detection Office have supported the development of new security inspection
technologies and products. Our Security division participates in a number of such research and development efforts, including projects to develop new technologies for radiation and nuclear materials
detection and aviation screening. The Science and Technology Directorate has also initiated programs for the development of technologies capable of protecting highways, railways and waterways from
terrorist attack.
In
addition, the U.S. Department of Defense has invested heavily in technologies and services that screen would-be attackers before they are able to harm U.S. and allied forces. These
technologies include products that can screen personnel, vehicles and other containers for the presence of explosives, improvised explosive devices (IEDs), weapons and other contraband.
The
U.S. Department of Energy (DOE) and other U.S. federal agencies implemented the Second Line of Defense Program and Megaports programs to help prevent the proliferation and
trafficking of radioactive and nuclear materials. The DOE has procured, and we continue to supply and maintain, multiple Rapiscan
radiation detection sensors, monitors and communications systems. Our Security division also directly supplies many countries, nuclear power facilities and industries handling radioactive materials
with radiation detection technology.
Similar
initiatives and new regulations promulgated by international organizations have resulted in a growing global demand for airline, cargo, port and border inspection technologies.
For example, the European Commission has issued uniform performance standards for systems that screen baggage and people at aviation checkpoints and air cargo, as well as new directives related
specifically to maritime security, among other security directives.
Major
projects recently installed or currently underway include installations at airports, ports and border crossings, government and military facilities and other locations in the
United States and throughout the world. These projects contain various inspection product offerings. We anticipate that there may be growing demand from governments and commercial enterprises for
increasingly sophisticated, turnkey and other security screening solutions.
Our
contracts with the U.S. Government are generally subject to renegotiation of profits and termination for convenience at the election of the Government. For the fiscal year ended
June 30, 2016, our direct sales to the U.S. Government were approximately $57 million. Additionally, certain of our contracts with foreign governments contain provisions allowing the
government to terminate a contract for convenience. For further discussion, please refer to "Item 1A. Risk Factors."
Healthcare.
Healthcare has been, and we believe will continue to be, a growing sector throughout much of the world. Developing
countries in Asia and
Latin America are expected to continue to build healthcare infrastructure to serve expanding middle class populations. In developed countries, including the United States and Europe, an aging
population and extended life expectancy is projected to fuel growth in healthcare for the foreseeable future.
Notwithstanding
this growth, many factors including stricter government requirements affecting staffing and accountability and shrinking reimbursements from health insurance
organizations are forcing healthcare providers to do more with less. At the same time, recent advances enabling big data management and analysis as well as the widespread introduction of mobile
devices into the healthcare environment, are creating an emerging demand for patient data acquisition and distribution. Our Healthcare division designs, manufactures and markets devices and software
that respond to these demands, helping hospitals reduce costs and more fully utilize resources while maintaining or improving the quality of care their physicians and nurses are able to deliver.
We
are a global manufacturer and distributor of patient monitoring, diagnostic cardiology and clinical networking solutions for use in hospitals, medical clinics and physician offices.
We design, manufacture and
4
Table of Contents
market
patient monitoring solutions for critical, perinatal, sub-acute and perioperative care areas of the hospital, wired and wireless networks and ambulatory blood pressure monitors, all aimed at
providing caregivers with timely patient information. Our diagnostic cardiology systems include Holter recorders and analyzers, ambulatory blood pressure monitors, electrocardiography (ECG) devices,
stress event data management systems and related software and services.
We
are also a global manufacturer and distributor of anesthesia delivery systems, ventilators and vaporizers. We sell these products primarily to hospitals for use in operating rooms and
anesthesia induction areas. We also sell subsystems and components, such as anesthesia vaporizers and ventilators, to pharmaceutical companies and other manufacturers of anesthesia delivery systems.
Under
the Primedic name, we are a global manufacturer and distributor of defibrillators outside the U.S. and Canada. We sell these products to emergency first responders and building
managers for general use in hospitals and other facilities, and emergency vehicles.
Optoelectronics and Manufacturing.
Our optoelectronic devices are used in a wide variety of applications for diversified markets
including the
aerospace and defense, avionics, medical imaging and diagnostics, biochemistry analysis, pharmaceutical, nanotechnology, telecommunications, construction and homeland security markets. Medical
applications for our devices include diagnostic and imaging products, patient monitoring equipment, and glucose monitors. Aerospace and defense applications for our devices include satellite
navigation sensors, laser guided munitions systems, range finders, weapons simulation systems, computer peripherals and other applications that require the conversion of optical signals into
electronic signals. Homeland security applications for our devices include X-ray based and other detection systems. Our optoelectronic devices and value-added subsystems are also used in a wide
variety of measurement control, monitoring and industrial applications and are key components in telecommunications technologies. We also offer electronics manufacturing services to our
optoelectronics customers, as well as to our Security and Healthcare divisions. We offer full turnkey and printed circuit board assembly, cable and harness assembly, liquid crystal displays and
box-build manufacturing services, in which we provide product design and development, supply chain management, and production manufacturing services.
We
believe that continued advances in technology and reductions in the cost of key components of optoelectronic systems, including computer processing power and memory, have broadened
the market by enabling the use of optoelectronic devices in a greater number of applications. In addition, we see a trend among OEMs to increasingly outsource the design and manufacture of
optoelectronic devices as well as value-added subsystems to fully-integrated, independent manufacturers, like us, that may have greater specialization, broader expertise and more flexibility to
respond to short cycle times and quicker market expectations. We believe that our level of vertical integration, substantial engineering resources, expertise in
the use and application of optoelectronic technology and low-cost international manufacturing operations enable us to compete effectively in the market for optoelectronic products and for electronics
manufacturing services.
We
have also penetrated several related markets that depend on our optoelectronic technologies and electronics manufacturing capabilities. Through system engineering and product
development, we also develop, manufacture and sell laser-based products, as well as sensors for vehicle classification in toll and traffic management systems.
Growth Strategy
We believe that one of our primary competitive strengths is our expertise in the cost-effective design and manufacture of specialized
electronic systems and components for critical applications. As a result, we have leveraged, and intend to continue to leverage, such expertise and capacity to gain price, performance and agility
advantages over our competitors in the security, healthcare and optoelectronics fields, and to translate such advantages into profitable growth in those fields. At the same time, we continually seek
to identify new markets in
5
Table of Contents
which
our core expertise and capacity will provide us with competitive advantages. Key elements of this strategy include:
Capitalizing on Global Reach.
We operate from locations throughout the world. We view our international operations as providing
an important
strategic advantage over competitors. First, our international manufacturing facilities allow us to take advantage of competitive labor rates and favorable tax regulations in order to be a low cost
producer. Second, our international offices strengthen our sales and marketing efforts and our ability to service and repair our systems by providing direct access to growing markets and to our
existing international customer base. Third, our international manufacturing locations allow us to reduce delivery times to our global customer base. In the future, we intend to continue to enhance
our international manufacturing and sales capabilities.
Capitalizing on Vertical Integration.
Our vertical integration provides several advantages in each of our divisions. These
advantages include reduced
manufacturing and delivery times, lower costs due to our access to competitive international labor markets and direct sourcing of raw materials. We also believe that we offer significant added value
to our customers by providing a full range of vertically-integrated services, including component design and customization, subsystem concept design and application engineering, product prototyping
and development, efficient pre-production and short-run and high volume manufacturing. We believe that our vertical integration differentiates us from many of our competitors and provides value to our
customers who can rely on us to be an integrated supplier. We intend to continue to leverage our vertical integration to create greater value for our customers in the design and manufacture of our
products.
Capitalizing on the Market for Security and Inspection Systems.
Attentiveness to terrorist and other security threats may
continue to drive the
market for security and inspection systems in transportation security and also at ports and border crossings, government installations, military facilities and public event venues. The trend toward
increased screening of goods entering and departing from ports and borders has resulted, and may continue to result in, the growth in the market for cargo inspection systems and turnkey security
screening services that are capable of screening shipping containers for contraband and assisting customs officials in the verification of shipping manifests. Package and cargo screening by freight
forwarders, airlines and air cargo companies represents a growing sector, as regulations in the United States and Europe require such screening in certain circumstances. We intend to capitalize on
opportunities to replace, service and upgrade existing security installations, and to offer turnkey security screening solutions in which we may construct, staff and/or operate on a long-term basis
security screening checkpoints for our customers. Finally, we also intend to continue to develop new security and inspection technologies, such as our proprietary real time tomography products, and to
enhance our current product and service offerings through internal research and development and selective acquisitions.
Improving and Complementing Existing Medical Technologies.
We develop and market patient monitoring systems, diagnostic
cardiology products,
anesthesia delivery systems, ventilators and vaporizers, defibrillators, and associated supplies and accessories. We are able to market and sell many of our product offerings through shared sales
channels and distribution networks. Our efforts to develop new products and improve our existing medical technologies are focused on the needs of care providers and their patients. Our efforts to
improve existing diagnostic cardiology and anesthesia delivery technologies will also continue to concentrate on providing products that are flexible and intuitive to use so that clinicians can
deliver accurate, precise, reliable and cost-effective care. We focus on enabling hospitals to leverage their IT infrastructure at a significant financial savings, providing actionable alarms at the
bedside monitor and the central station.
Selectively Entering New Markets.
We intend to continue to selectively enter new markets that complement our existing
capabilities in the design,
development and manufacture of specialized electronic systems and components for critical applications such as security inspection and patient monitoring, diagnostic cardiology and anesthesia systems.
We believe that by manufacturing products that rely on our existing technological
capabilities, we will leverage our integrated design and manufacturing infrastructure to build a larger presence in new markets
6
Table of Contents
that
present attractive competitive dynamics. We intend to achieve this strategy through internal growth and through selective acquisitions.
Acquiring New Technologies and Companies.
Our success depends in part on our ability to continually enhance and broaden our
product offerings in
response to changing technologies, customer demands and competitive pressures. We have developed expertise in our various lines of business and other areas through internal research and development
efforts, as well as through selective acquisitions. In addition to our pending acquisition of AS&E, we expect to continue to seek acquisition opportunities to broaden our technological expertise and
capabilities, lower our manufacturing costs and facilitate our entry into new markets.
Products and Technology
We design, develop, manufacture and sell products ranging from security and inspection systems to patient monitoring, cardiology and
anesthesia systems to discrete optoelectronic devices and value-added subsystems.
Security and Inspection Systems.
We design, manufacture and market security and inspection systems globally to end users under
the "Rapiscan Systems"
trade name. Rapiscan Systems products are used to inspect baggage, parcels, cargo, people, vehicles and other objects for weapons, explosives, drugs, radioactive and nuclear materials and other
contraband. These systems are also used for the safe, accurate and efficient verification of cargo manifests for the purpose of assessing duties and monitoring the export and import of controlled
materials. Rapiscan Systems products fall into the following categories: baggage and parcel inspection; cargo and vehicle inspection; hold (checked) baggage screening; people screening; radiation
detection; and explosive and narcotics trace detection. We also offer turnkey security screening services under the "S2" trade name, including the staffing and operation of security screening
checkpoints.
As
a result of the terrorist attacks of September 11, 2001, and subsequent attacks in other locations worldwide, security and inspection products have increasingly been used at a
wide range of facilities other than airports, such as border crossings, railways, seaports, cruise line terminals, freight forwarding operations, government and military installations and nuclear
facilities. As a result of the use of security and inspection products at additional facilities, we have diversified our sales channels for security and inspection products.
Many
of our security and inspection systems include dual-energy X-ray technology with computer software enhanced imaging technology to facilitate the detection of materials such as
explosives, weapons, narcotics, bulk currency or other contraband. While all X-ray systems produce a two-dimensional image of the contents of the inspected object, the dual-energy X-ray systems also
measure the X-ray absorption of the inspected object's contents at two different X-ray energies to determine the atomic number, mass and other characteristics of the object's contents. The various
organic and inorganic substances in the inspected object appear to operators of the inspection systems in various colors, and this visual information can be used to identify and differentiate the
inspected materials. In addition, we offer dual-view X-ray screening systems, now available on many of our systems that allow operators to examine objects from two orthogonal positions simultaneously,
thereby reducing the need for re-scanning of objects and improving the operator's ability to detect threats quickly and effectively. Our baggage and parcel inspection, cargo and vehicle inspection and
hold (checked) baggage screening inspection systems range in size from compact mobile systems to large systems comprising entire buildings in which trucks, shipping containers or pallets are
inspected. Many of our inspection systems are also designed to be upgradeable to respond to new customer requirements as they emerge or change.
Our
cargo and vehicle inspection applications, in which occupied vehicles, cars, trucks, shipping containers, pallets and other large objects can be inspected, are designed in various
configurations, including fixed-site, gantry, relocatable, portal and mobile systems. These products are primarily used to verify the contents of cars, trucks or cargo containers and to detect the
presence of contraband, including narcotics, weapons, explosives, radioactive and nuclear materials and other smuggled items. They offer significant improvements over past methods of cargo
7
Table of Contents
screening,
such as manual searches, as our cargo systems are faster, more thorough and do not subject the cargo to pilferage. Entire shipping containers or trucks containing densely packed goods can
be screened rapidly.
Most
of our cargo and vehicle inspection systems are based on high energy X-ray technology, in conjunction with digital imaging equipment, to non-intrusively inspect objects and present
images to an inspector, showing shapes, sizes, locations and relative densities of the contents. We also manufacture passive radiation detection devices for detecting nuclear threat material utilizing
their gamma and neutron signatures. Additionally, we have developed isotope specific identification algorithms. Many of these systems have been built to meet specific customer inspection requirements.
Our
Security division is among the only companies in the market offering inspection systems at energy levels ranging from 140 Kilo electron Volts (KeV) to 160 KeV, 180 KeV, 200 KeV, 320
KeV, 1 Mega electron Volt (MeV), 4.5 MeV, 6 MeV, and 9MeV. We believe that we offer one of the broadest technology platforms in the baggage and parcel and cargo and vehicle inspection systems
industry. Our broad platform permits us to offer customers solutions, which optimize flexibility, performance and cost to meet the customer's unique application requirements.
Our
Security division also offers hold (checked) baggage screening systems that are utilized by airports, freight forwarders and other parties responsible for screening baggage and cargo
before it is placed in the cargo hold of airplanes. Certain of our currently available systems utilize multiple, dual-energy X-ray beams to provide high-quality images and to enable algorithms that
assist operators in the detection of explosives. Other systems utilize a very large number of distributed X-ray emitters that rapidly capture approximately 1,000 views of a bag and then utilize
sophisticated software to reconstruct high resolution images. These systems are designed to meet the high-speed screening and analysis demands of regulators in the United States and European Union.
They can be operated in stand-alone mode, where a single operator views the images produced by a single system, or can be networked, allowing operators stationed at a remote computer terminal to
monitor multiple systems.
Our
Security division also offers people screening products, such as a line of "Metor" brand walk-through metal detector (WTMD) products for use at security checkpoints at airports,
amusement parks, banks, courthouses, government buildings, sports arenas and other venues, and the Counterbomber line of suicide bomber detection products. We have also developed a high performance
hand-held trace detection system providing portable light-weight detection of trace amounts of explosives as well as narcotics. This system is designed to be used in screening people, cargo, baggage
and other items for illicit materials and weapons.
8
Table of Contents
The following table sets forth certain information related to the standard security and inspection products that we currently offer. We do, however, also
customize our standard products to suit specific applications and customer requirements.
|
|
|
|
|
|
|
PRODUCT LINE
|
|
PRODUCT NAME /
PRODUCT FAMILY
|
|
TECHNOLOGY
|
|
MARKET SEGMENT
|
Baggage and Parcel Inspection
|
|
Rapiscan 600 series
X-ray systems
|
|
Dual-energy X-ray
Single and multi-view configuration
|
|
Checkpoint inspection at airports, prisons, border crossings, government buildings, and postal facilities, critical infrastructure protection at power and chemical plants, water resource sites as well as air cargo
screening
|
|
|
|
|
|
|
|
Cargo and Vehicle Inspection
|
|
Rapiscan Eagle
|
|
High energy X-ray
|
|
Occupied vehicle, cars, cargo, vehicle and rail car inspection at airports, border crossings and sea ports
|
|
|
|
|
|
|
|
Hold (Checked) Baggage Screening
|
|
Rapiscan MVXR 5000
Rapiscan RTT
|
|
Multi-view, dual energy X-ray explosive detection system (EDS)
High-speed, stationary gantry computed tomography explosive detection system (EDS)
|
|
Baggage inspection with automatic explosive detection at airports and freight forwarding facilities
|
|
|
|
|
|
|
|
People Screening
|
|
Metor series metal detectors
Rapiscan Secure 1000
Counterbomber
|
|
Electromagnetic induction
Backscatter X-ray
Radar and video tracking
|
|
Checkpoint inspection at airports, border crossings, military checkpoints, stadiums, prisons and government facilities
|
|
|
|
|
|
|
|
Radiation Detection
|
|
Rapiscan Radiation Monitors
|
|
Gamma and neutron detection of radioactive and nuclear material
|
|
Cargo, vehicle, rail car and people screening at airports, border crossings, military checkpoints, stadiums, prisons and government facilities
|
|
|
|
|
|
|
|
Trace Detection
|
|
Detectra
|
|
IMS based technology hand-held explosives and narcotics detection
|
|
Checkpoint inspection at airports, border crossings, military checkpoints, stadiums, prisons and government facilities
|
Patient Monitoring, Diagnostic Cardiology, Anesthesia Systems and Defibrillators.
Our Healthcare division designs, manufactures
and markets products
globally to end users primarily under the "Spacelabs", "Primedic" and "Statcorp" trade names.
Spacelabs
products include patient monitors for use in perioperative, critical care and emergency care environments with neonatal, pediatric and adult patients. Our patient monitoring
systems comprise monitors and central nursing stations connected by hardwired or wireless networks, as well as stand-alone monitors where the patient data can be transported physically from one
monitor to another as the patient is moved. These systems enable hospital staff to access patient data where and when it is required. In addition, these products are designed
9
Table of Contents
with
an "open architecture" to interact with hospital information systems. Many of these products allow clinicians to view and control various software applications on the patient monitor's display,
eliminating the need for separate computer terminals in the patient's room. Attending nurses can check laboratory results and other reports, enter orders, review protocols and complete medical
charting at the patient's bedside.
For
electrocardiograph monitoring or multiparameter monitoring of ambulatory patients, we offer a digital telemetry system. The system operates in government-protected bands, which are
not used for private land mobile radio, business radio services or broadcast analog or digital television. Spacelabs Intesys® Clinical Suite (ICS) provides a software suite allowing
hospitals to leverage their infrastructure to capture all data from the bedside, compact and telemetry monitors. Retrospective data formerly only found at a central station monitor is made available
at any PC in the hospital.
In
the past few years, Spacelabs has introduced a number of new products, including the XPREZZON® patient monitor, followed shortly by the qube® compact monitor.
The qube can be used in both bedside and transport applications. We also introduced a new telemetry transmitter, the AriaTele, with subsequent product additions to enable the
AritaTele
TM
to broadcast on a number of specialized frequency bands that are prescribed for global healthcare use. Other recent product introduction were the Xhibit® Central
Station, a scalable system providing
clinicians the ability to remotely monitor up to 48 patients and the XprezzNet
TM
, a high resolution data integration for electronic medical records vendor Cerner, which provides unique
patient to device association (P2DA). In June 2015, we introduced the XTR telemetry system. XTR provides a proprietary arrhythmia detection algorithm, which continuously analyzes and displays seven
leads of ECG on Xhibit or in ICS clinical access.
In
2016, we introduced two new software products designed to drive greater efficiency and accountability in the workflow of hospitals. Spacelabs TeleCom enables hospitals to
connect, track, communicate and report on all patient monitoring. Positive patient-to-device association using a hospital's existing smartphones or roving workstations can help reduce errors related
to patient safety and device management. Electronic tracking and recording of communications helps to eliminate the traditional reliance on faxing, scanning, printing and storing of paper records to
document caregiver communications. Spacelabs SafeNSound can help hospitals meet the Joint Commission's National Patient Safety Goals related to alarm reporting and alarm fatigue
management. Both Spacelabs TeleCom and Spacelabs SafeNSound feature detailed reports that can assist in compliance and audits.
Our
Healthcare division also develops cardiac diagnostic systems, including Holter analyzers and recorders. Our PathfinderSL analysis tool provides simple, actionable Holter reports to
any PC, inside or outside the hospital. Our evo® Holter recorders provide low cost of ownership through, for example, the elimination of disposable batteries, memory cards with no moving
parts to maintain and other advances. Our Lifecard CF Holter recorders are worn by patients for up to seven days in order to capture heart arrhythmias that may occur in a patient only a few times per
week. This product is especially helpful in identifying the presence of atrial fibrillation. Patients that may be experiencing even less frequent heart arrhythmias wear our CardioCall product, which
stays with the patient over several weeks and transmits its findings over the phone to a receiving station in the hospital. Our Cambridge Heart HearTwave II® Stress Testing System product
provides vital information during an exercise stress test using the optional Microvolt T-Wave Alternans test that is designed to help identify patients at risk of sudden cardiac death.
We
are also a supplier of ambulatory blood pressure (ABP) monitors which are routinely used by physicians around the world and by clinical research organizations. Many physicians are
using ambulatory blood pressure monitoring to detect "white coat" hypertension, a condition in which people experience elevated blood pressure in the doctor's office but not in their daily lives.
Ambulatory blood pressure monitoring helps improve diagnostic accuracy and minimize the associated costs of treatment. In 2014, we introduced the OnTrak ambulatory blood pressure system. This system
provides the first ambulatory blood pressure monitor to be validated for both pediatric and adult patient types and includes the capability to measure activity correlation with non-invasive blood
pressure readings.
10
Table of Contents
We
also provide the Sentinel Cardiology Information Management System, which integrates data from Spacelabs-branded products into a central enterprise-wide database system that can be
accessed by care providers and medical facility administrators thereby providing enhanced workflow and efficiencies. In 2015, we introduced a thin client version of Sentinel that enables clinicians to
easily interact with remote, centralized databases using their standard browser on PCs, tablets and cell phones. Sentinel 10 supports a zero IT deployment model with smart applets downloaded to user
PC devices on demand, simplifying roll-out and maintenance from an IT perspective.
Our
anesthesia delivery and ventilation group designs and manufactures anesthesia delivery systems, vaporizers and ventilators. The ARKON Anesthesia System is a high-performance
anesthesia delivery system that offers functionality, comfort and control. This anesthesia delivery system can be expanded to enable a wide-angle view of the clinical setting so the clinician can face
the patient, as well as other clinical advancements. The ARKON complements our BleaseSirius, BleaseFocus and BleaseGenius anesthesia delivery systems. With this broad portfolio of anesthesia systems,
we can provide flexible anesthesia solutions for operating room environments, anesthesia induction areas, day surgery centers, magnetic resonance imaging facilities and other locations where the
administration of anesthesia is required. Our BleaseDatum anesthesia vaporizers and Blease 700/900 anesthesia ventilators are also designed to be compatible with the anesthesia delivery systems of
several other manufacturers.
Our
defibrillator products are distributed under the Primedic brand name. The HeartSave One products are for use by public first responders, while the HeartSave 6/6S and DefiMonitor
products are for use by medical personnel.
Many
of the capital-intensive products that Spacelabs sells have supplies and accessories associated with them that can represent annuity revenue opportunities. Recognizing this, we
integrated Statcorp Medical, which manufactures blood pressure cuffs and rapid infusor bags, into Spacelabs. Statcorp Medical has recently introduced bariatric cuffs providing improved blood pressure
measurements from patients with larger arms, as well as patient cables that allow transition between different devices without the need to recable.
11
Table of Contents
The
following table sets forth a description of the more significant healthcare products that we currently offer:
|
|
|
|
|
PRODUCT LINE
|
|
PRODUCT NAME /
PRODUCT FAMILY
|
|
MARKET SEGMENT
|
Patient Monitoring and Connectivity
|
|
XPREZZON
qube
Ultraview DM3 Dual Monitor
Intesys Clinical Suite G2
ICS Xprezz
XprezzNet
Flexports
Sonicaid Fetal Monitor
Xhibit
élance
AriaTele
Spacelabs TeleCom
Spacelabs SafeNSound
|
|
Hospital care areas, outpatient surgery centers and physician offices
|
|
|
|
|
|
Diagnostic Cardiology
|
|
Ambulatory blood pressure monitors (various)
OnTrak ABP
Pathfinder SL
CardioCall
Lifecard
evo
CardioExpress ECG machines
CardioDirect Stress Testing Systems
Sentinel Cardiology Data Management
HearTwave II® Stress Testing System
|
|
Hospital cardiology care areas and physician offices
|
|
|
|
|
|
Anesthesia Delivery and Ventilation
|
|
ARKON
Blease 700 and 900 series ventilators
BleaseSirius
BleaseSirius EFM
BleaseDatum Vaporizer
BleaseFocus
BleaseGenius
|
|
Ambulatory surgery centers and operating rooms
|
|
|
|
|
|
Defibrillators
|
|
HeartSave One / PAD / AED / AED-M / AS
HeartSave 6/6S
DefiMonitor XD / EVO
|
|
Emergency first responders and building management
|
|
|
|
|
|
Medical Devices and Accessories
|
|
UltraCheck, SoftCheck and Curve Blood Pressure Cuffs
Patient Cables and Accessories
Fluid Delivery Unifusors
|
|
All hospital care areas, outpatient surgery centers and physician offices
|
Optoelectronic Devices and Manufacturing Services.
Optoelectronic devices generally consist of both active and passive
components. Active components
sense light of varying wavelengths and convert the light
12
Table of Contents
detected
into electronic signals, whereas passive components amplify, separate or reflect light. The active components we manufacture consist of silicon, gallium arsenide and indium gallium arsenide
photodetectors and light sources. Passive components include lenses, prisms, filters, mirrors and other precision optical products that are used by us in the manufacture of our optoelectronic products
or are sold to third parties for use in telescopes, laser printers, copiers, microscopes and other detection and vision equipment. The devices we manufacture are both standard products and products
customized for specific applications and are offered either as components or as subsystems. Our optoelectronic products and services are provided primarily under the "OSI Optoelectronics" trade name.
In
addition to the manufacture of standard and OEM products, we also specialize in designing and manufacturing customized value-added subsystems for use in a wide range of products and
equipment. An optoelectronic subsystem typically consists of one or more optoelectronic devices that are combined with other electronic components and packaging for use in an end product. The
composition of a subsystem can range from a simple assembly of various optoelectronic devices that are incorporated into other subsystems (for example, a printed circuit board containing our
optoelectronic devices) to complete end-products (for example, pulse oximetry equipment).
We
also provide electronics design and manufacturing services both in North America, the United Kingdom and in the Asia Pacific region with enhanced, RoHS-compliant, printed circuit
board and cable and harness assemblies and box-build manufacturing services utilizing state-of-the-art automated surface mount technology lines. We offer electronics manufacturing services to OEM
customers and end users for medical, automotive, defense, aerospace, industrial and skin care applications that do not utilize optoelectronic devices. We also manufacture LCD displays for medical,
industrial and consumer electronics applications, and flex curcuits and touch panels for OEM customers at the prototype stage. Our electronics manufacturing services are provided primarily under the
"OSI Electronics," "APlus Products," "Briton EMS," "Union Four" and "Altaflex" trade names.
We
develop, manufacture and sell laser-based remote sensing devices that are used to detect and classify vehicles in toll and traffic management systems under the "OSI Laserscan" and
"Autosense" trade names. We offer solid-state laser products for aerospace, defense, telecommunication and medical applications under the "OSI LaserDiode" trade name.
13
Table of Contents
The
following table sets forth a description of the more significant standard optoelectronics products that we currently offer. We also customize our standard products to suit specific
applications and customer requirements.
|
|
|
|
|
PRODUCT LINE
|
|
PRODUCT NAME /
PRODUCT FAMILY
|
|
MARKET SEGMENT
|
Optoelectronic Components
|
|
Si and InGaAs Photodiodes and Avalanche Diodes
UV and XUV
Linear and 2-D Arrays X-Ray Photodetectors
Position Sensitive Devices
Optical Switches
Silicon and InGaAs Telecom Devices
Solid State Laser Diodes
Laser Scanners (AS600 through AS800 Series)
|
|
Medical diagnostics instrumentation and analytical chemistry, oximetry and blood chemistry, barcode readers, security scanners and inspection systems, lidar and laser range finder, OTDR and test and measurement
instruments, laser guided munitions, weapon simulation systems, aircraft gyro navigation sensors, satellite sun acquisition sensors, electronic toll collection (ETC) and toll and traffic management systems and laser scanners.
|
|
|
|
|
|
Medical Devices and Accessories
|
|
Oximetry Sensors and Accessories
|
|
Medical devices and instrumentation
|
|
|
|
|
|
Toll and Traffic Management Systems, Laser Scanners
|
|
|
|
Laser based scanners and ETC hardware and software
|
Markets, Customers and Applications
Security and Inspection Products.
Many security and inspection products were developed in response to civilian airline
hijackings. Consequently, a
significant portion of our security and inspection products have been and continue to be sold for use at airports. Our security and inspection products are also used for security purposes at locations
in addition to airports, such as border crossings, shipping ports, military and other government installations, freight forwarding facilities, high-profile locations such as U.K. House of Parliament,
Buckingham Palace, the Kremlin and the Vatican and for high-profile events such as the Olympic Games. Furthermore, as terrorist attacks continue to occur, overall transportation and travel industry
demands have increased, resulting in heightened attention for our security and inspection products. We also provide turnkey security screening solutions, which can include the construction, staffing
and long-term operation of security screening locations for our customers.
Our
customers include, among many others, the U.S. Customs and Border Protection, U.S. Department of Defense, U.S. Transportation Security Administration and Federal Bureau of Prisons in
the United States, as well as Her Majesty's Revenue and Customs and Manchester Airport Group in the United Kingdom, Aeroporto Di Paris, Aeroporto De Roma, the Servicio de Administración
Tributaria in México, Chek Lap Kok Airport in Hong Kong and Ben Gurion International Airport in Israel, DHL, and United Parcel Service.
Patient Monitoring, Diagnostic Cardiology, Anesthesia Systems and Defibrillators.
Our patient monitoring, diagnostic cardiology
and anesthesia
systems are manufactured and distributed globally for use in critical care, emergency and perioperative areas within hospitals as well as physicians' offices, medical clinics and ambulatory surgery
centers. We also provide wired and wireless networks, clinical information access solutions and ambulatory blood pressure monitors. Our defibrillators are manufactured and distributed globally for use
in public facilities, medical facilities and ambulances.
14
Table of Contents
We
have sold products to organizations such as Eisenhower Medical Center in Rancho Mirage, California, Spartanburg Regional Medical Center in Spartanburg, South Carolina, LSU Medical
Center in Shreveport, Louisiana, the Kingston Hospital NHS Foundation Trust in the United Kingdom, Centre Hospitalier Saint JosephSaint Luc and CHU
BordeauxHôpital Pellegrin in France, among many other organizations. We have also sold the products through various group purchasing organizations, including
Vizient, Inc., Healthtrust Purchasing Group, L.P., MedAssets Supply Chain Systems, LLC, and Premier, Inc., among others.
Optoelectronic Devices and Electronics Manufacturing Services.
Our optoelectronic devices and the electronics we manufacture are
used in a broad
range of products by a variety of customers. For example, they are utilized by customers in the following market segments: defense, aerospace and avionics; analytical and medical imaging; healthcare;
telecommunications; homeland security; barcode scanners; toll and traffic management; and automotive diagnostic systems. Major customers in these segments include Apple, Tesla, Google, Raytheon,
Honeywell, UTC Aerospace Systems, Northrop Grumman, Medtronic, Smiths Medical, Conmed Corporation, Draeger Medical, Beckman Coulter, FireEye, United Technologies, Draeger Safety, Pacific Bioscience
Laboratories, Vislink, Assa Aboy and Trakka, among others.
Marketing, Sales and Service
We market and sell our security and inspection products and turnkey security screening solutions globally through a direct sales and
marketing staff located North America, Latin America, Europe, Middle East, Africa, Asia and Australia, in addition to an expansive global network of independent distributors. This sales staff is
supported by a service organization located in the same regions, as well as a global network of independent distributors. We also support these sales and customer relations efforts by providing
operator training, computerized training and testing equipment, in-country service support, software upgrades and service training for customer technicians.
We
market and sell our patient monitoring, diagnostic cardiology, anesthesia systems and defibrillators globally through a direct sales and marketing staff located in North America,
Latin America, Europe and Asia, in addition to a global network of independent distributors. We also support these sales and customer service efforts by providing operator in-service training,
comprehensive interactive eLearning for all monitoring products, software updates and upgrades and service training for customer biomedical staff and distributors. We also provide IT specialists and
clinical specialists to provide support both before and after product sale.
We
market and sell our optoelectronic devices and value-added manufacturing services, through both a direct sales and marketing staff located in North America, Europe and Asia, and
indirectly through a global network of independent sales representatives and distributors. Our sales staff is supported by an applications
engineering group whose members are available to provide technical support, which includes designing applications, providing custom tooling and process integration and developing products that meet
customer defined specifications.
We
consider our maintenance service operations to be an important element of our business. After the expiration of our standard product warranty periods, we are sometimes engaged by our
customers to provide maintenance services for our security and inspection products through annual maintenance contracts. In addition, we believe that our expertise in installing, maintaining and
operating our security inspection products is an important factor for customers that are considering engaging us to provide turnkey security screening solutions. We provide a variety of service and
support options for our healthcare customers, including complete hospital on-site repair and maintenance service and telephone support, parts exchange programs for customers with the internal
expertise to perform a portion of their own service needs and a depot repair center at our division headquarters. We believe that our international maintenance service capabilities allow us to be
competitive in selling our security and inspection systems as well as our patient monitoring, diagnostic cardiology and anesthesia systems. Furthermore, we believe that as the installed base of both
our security and inspection systems and patient monitoring, diagnostic cardiology and anesthesia systems increases, revenues generated from such annual maintenance service contracts and from the sale
of replacement parts will increase.
15
Table of Contents
Research and Development
Our security and inspection systems are primarily designed at our facilities in the United States and internationally in the United
Kingdom, Finland and India. These products include mechanical, electrical, analog and digital electronics, software subsystems and algorithms, which are all designed by us. In addition to product
design, we provide system integration services to integrate our products into turnkey systems at the customer site. We support cooperative research projects with government agencies and provide
contract research for government agencies.
Our
patient monitoring, diagnostic cardiology, anesthesia delivery and defibrillator products are primarily designed at our facilities in the United States and internationally in China,
Germany and the United Kingdom. These products include software, networking, connectivity, mechanical, electrical, digital electronic and software subsystems, most of which are designed by us. We are
also currently involved, both in the United States and internationally, in several research projects aimed at improving our medical systems and at expanding our current product lines.
We
design and manufacture optoelectronic devices and we provide electronics manufacturing services primarily in our facilities in the United States and internationally in the United
Kingdom, India, Indonesia, Malaysia and Singapore. We engineer and manufacture subsystems to solve the specific application needs of our OEM customers. In addition, we offer entire subsystem design
and manufacturing solutions. We consider our engineering personnel to be an important extension of our core sales and marketing efforts.
In
addition to close collaboration with our customers in the design and development of our current products, we maintain an active program for the development and introduction of new
products, enhancements and improvements to our existing products, including the implementation of new applications of our technology. We seek to further enhance our research and development program
and consider such program to be an important element of our business and operations. As of June 30, 2016, we engaged approximately 421 full-time engineers, technicians and support staff. Our
research and development expenses were $44.8 million in fiscal 2014, $51.6 million in fiscal 2015 and $49.8 million in fiscal 2016. We intend to continue to invest in our research
and development efforts in the future.
Manufacturing and Materials
We currently manufacture our security and inspection systems domestically in California, Colorado, Virginia and North Carolina, and
internationally in Malaysia and the United Kingdom. We currently manufacture our patient monitoring, diagnostic cardiology, anesthesia systems, defibrillators and related supplies and accessories
domestically in Washington and internationally in China and Germany. We outsource manufacturing of certain of our diagnostic cardiology supplies and accessories. We currently manufacture our
optoelectronic devices and provide electronics manufacturing services domestically in California and New Jersey, and internationally in India, Indonesia, Malaysia, the United Kingdom and Singapore.
Most of our high volume, labor intensive manufacturing and assembly activities are performed at our facilities in India, Indonesia and Malaysia. Since many of our customers are located in the United
States, Europe and Asia, our ability to manufacture products in these markets and provide follow-on service from offices located in these regions is an important component of our global strategy.
Our
global manufacturing organization has expertise in optoelectronic, microelectronic and integrated electronics for industrial and automation, medical, aerospace and defense industry
applications. Our manufacturing includes silicon wafer processing and fabrication, optoelectronic device assembly and screening, thin and thick film microelectronic hybrid assemblies, surface mounted
and thru-hole printed circuit board electronic assemblies and electronics services, including complete turnkey and box-build manufacturing, and flex circuitry. We outsource certain manufacturing
operations, including certain sheet metal fabrication and plastic components.
16
Table of Contents
The principal raw materials and subcomponents used in producing our security and inspection systems consist of X-ray generators, linear accelerators, radioactive
isotopes, detectors, data acquisition and computer systems, conveyance systems and miscellaneous mechanical and electrical components. A large portion of the optoelectronic devices, subsystems and
circuit card assemblies used in our inspection and detection systems are manufactured in-house. The majority of our X-ray generators, linear accelerators, radioactive isotopes and conveyance systems
used in our cargo and vehicle inspection systems are purchased from unaffiliated third party providers.
The
principal raw materials and subcomponents used in producing our patient monitoring, diagnostic cardiology and anesthesia systems and related supplies and accessories consist of
printed circuit boards, housings, mechanical assemblies, pneumatic devices, touch screens, medical grade displays, cables, filters,
textiles, fabric, gauges, fittings, tubing and packaging materials. We purchase certain devices, including computers, peripheral accessories and remote displays, from unaffiliated third party
providers.
The
principal raw materials and subcomponents used in producing our optoelectronic devices and electronic subsystems consist of silicon wafers, electronic components, light emitting
diodes, scintillation crystals, passive optical components, printed circuit boards and packaging materials. The silicon- based optoelectronic devices manufactured by us are critical components in most
of our products and subsystems. We purchase silicon wafers and other electronic components from unaffiliated third party providers.
For
cost, quality control and efficiency reasons, at times we purchase raw materials and subcomponents only from single vendors with whom we have ongoing relationships. We do, however,
qualify second sources for many of our raw materials and critical components. We purchase the materials pursuant to purchase orders placed from time to time in the ordinary course of business.
Although to date none of our divisions has experienced any significant shortages or material delays in obtaining any of its raw materials or subcomponents, it is possible that we may face such
shortages or delays in one or more materials in the future.
Trademarks and Tradenames, Patents, and Licenses
Trademarks and Tradenames.
We have used, registered and applied to register certain trademarks and service marks to distinguish
our products,
technologies and services from those of our competitors in the United States and in foreign countries. We enforce our trademark, service mark and trade name rights in the United States and abroad.
Patents.
We possess rights to a number of U.S. and foreign patents relating to various aspects of our security and inspection
products, healthcare
products and optoelectronic devices and subsystems. Our current patents will expire at various times between 2016 and 2035. However, it remains possible that pending patent applications or other
applications that may be filed may not result in issued patents. In addition, issued patents may not survive challenges to their validity or enforceability, or may be found to not be infringed by any
third parties. Although we believe that our patents have value, our patents, or any additional patents that may be issued in the future, may not be able to provide meaningful protection from
competition.
Licenses.
Our Security, Healthcare and Optoelectronics and Manufacturing divisions have each entered into a variety of license
arrangements under
which certain third parties are permitted to manufacture, market, and/or sell a limited number of the products that we offer and/or to service various types of software, data, equipment, components
and enhancements to our own proprietary technology.
We
believe that our trademarks and tradenames, patents and licenses are important to our business. The loss of some of our trademarks, patents or licenses might have a negative impact on
our financial results and operations. Nevertheless, with the exception of the loss of either the Spacelabs® or Rapiscan® trademarks, the impact of the loss of any single
trademark, patent or license would not likely have a material adverse effect on our business. As of
17
Table of Contents
June 30,
2016, the Spacelabs brand is protected by both pending and registered trademarks in 29 countries; and the Rapiscan brand is protected by both pending and registered trademarks in 19
countries.
Regulation of Medical Devices
The patient monitoring, diagnostic cardiology and anesthesia systems we manufacture and market are subject to regulation by numerous
government agencies, principally the U.S. Food and Drug Administration (FDA), and by other federal, state, local and foreign authorities. These systems are also subject to various U.S. and foreign
electrical safety standards. Our medical device product candidates must undergo an extensive government regulatory clearance or approval process prior to sale in the United States and other countries,
and the lengthy process of clinical development and submissions for approvals, as well as the continuing need for compliance with applicable laws and regulations, require the expenditure of
substantial resources.
United States.
In the United States, the FDA has broad regulatory powers with respect to pre-clinical and clinical testing of
new medical devices and
the designing, manufacturing, labeling, storage, record keeping, marketing, advertising, promotion, distribution, post-approval monitoring and reporting and import and export of medical devices.
Unless an exemption applies, federal law and FDA regulations require that all new or significantly modified medical devices introduced into the market be preceded either by a pre-market notification
clearance order under section 510(k) of the Federal Food, Drug and Cosmetic Act (FDCA), or an
approved pre-market approval (PMA) application. Under the FDCA, medical devices are classified into one of three classesClass I, Class II or
Class IIIdepending on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurances with respect to safety and
effectiveness. Class I devices are those for which safety and effectiveness can be reasonably assured by adherence to a set of regulations, referred to as General Controls, which require
compliance with the applicable portions of the FDA's Quality System Regulation (QSR) facility registration and product listing, reporting of adverse events and malfunctions, and appropriate, truthful
and non-misleading labeling and promotional materials. Some Class I devices, also called Class I reserved devices, also require premarket clearance by the FDA through the 510(k)
premarket notification process described below. Most Class I products are exempt from the premarket notification requirements.
Class II
devices are those that are subject to the General Controls, as well as Special Controls, which can include performance standards, guidelines and post-market surveillance.
Most Class II devices are subject to premarket review and clearance by the FDA. Premarket review and clearance by the FDA for Class II devices is accomplished through the 510(k)
premarket notification process. Under the 510(k) process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the product for which clearance has been sought is
substantially equivalent to a previously cleared 510(k) device or a device that was in commercial distribution before May 28, 1976 for which the FDA had not yet called for the submission of
pre-market approval applications. To be substantially equivalent, the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as
the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes required to
support substantial equivalence.
After
a 510(k) notice is submitted, the FDA determines whether to accept it for substantive review. If it lacks necessary information for substantive review, the FDA will refuse to
accept the 510(k) notification. If it is accepted for filing, the FDA begins a substantive review. By statute, the FDA is required to complete its review of a 510(k) notification within 90 days
of receiving the 510(k) notification. As a practical matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared without clinical
data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees
that the device is substantially equivalent, it will grant clearance to commercially market the device.
18
Table of Contents
After
a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change in its intended
use, will require a new 510(k) clearance or, depending on the modification, could require a PMA application. The FDA requires each manufacturer to make this determination initially, but the FDA can
review any such decision and can disagree with a manufacturer's determination. If the FDA disagrees with a manufacturer's determination regarding whether a new premarket submission is required for the
modification of an existing device, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or approval of a PMA application is obtained. If
the FDA requires us to seek 510(k) clearance or approval of a
PMA application for any modifications to a previously cleared product, we may be required to cease marketing or recall the modified device until we obtain this clearance or approval. In addition, in
these circumstances, we may be subject to significant regulatory fines or penalties for failure to submit the requisite PMA application(s). In addition, the FDA is currently evaluating the 510(k)
process and may make substantial changes to industry requirements.
Class III
devices include devices deemed by the FDA to pose the greatest risk such as life-supporting or life-sustaining devices, or implantable devices, in addition to those
deemed not substantially equivalent following the 510(k) process. The safety and effectiveness of Class III devices cannot be reasonably assured solely by the General Controls and Special
Controls described above. Therefore, these devices are subject to the PMA application process, which is generally more costly and time consuming than the 510(k) process. To date, all of the patient
monitoring, diagnostic cardiology and anesthesia systems we manufacture and sell in the United States have required only 510(k) pre-market notification clearance.
FDA
clearance or approval, when granted, may entail limitations on the indicated uses for which a product may be marketed, and such product approvals, once granted, may be withdrawn if
problems occur after initial marketing. Manufacturers of FDA-regulated products are subject to pervasive and continuing governmental regulation, including, but not limited to, the registration and
listing regulation, which requires manufacturers to register all manufacturing facilities and list all medical devices placed into commercial distribution; the QSR, which requires manufacturers,
including third party manufacturers, to follow elaborate design, testing, production, control, supplier/contractor selection, complaint handling, documentation and other quality assurance procedures
during the manufacturing process; labeling regulations and unique device identification requirements; advertising and promotion requirements; restrictions on sale, distribution or use of a device; PMA
annual reporting requirements; the FDA's general prohibition against promoting products for unapproved or "off-label" uses; the Medical Device Reporting (MDR) regulation, which requires that
manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury
if it were to reoccur; medical device correction and removal reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken
to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health; recall requirements, including a mandatory recall if there is a reasonable
probability that the device would cause serious adverse health consequences or death; an order of repair, replacement or refund; device tracking requirements; and post-approval study and post-market
surveillance requirements. The FDA has also established a Unique Device Identification ("UDI") system that will be phased in over several years. The UDI system requires manufacturers to mark certain
medical devices distributed in the United States with unique device identifiers.
Our
facilities, records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. Failure to comply with the applicable United States medical device
regulatory requirements could result in, among other things, warning letters, untitled letters, fines, injunctions, consent decrees, civil penalties, unanticipated expenditures, repairs, replacements,
refunds, recalls or seizures of products, operating restrictions, total or partial suspension of production, the FDA's refusal to issue certificates to foreign governments needed to export products
for sale in other countries, the FDA's refusal to grant future premarket clearances or approvals, withdrawals or suspensions of current product clearances or approvals and criminal prosecution.
19
Table of Contents
In
August 2014, the FDA issued a warning letter to our Healthcare division relating primarily to the maintenance of certain procedures and internal processes at our facility in
Snoqualmie, Washington. We have implemented corrective actions as a result of the warning letter and provided the FDA with a detailed response regarding our completed and in process activities.
However, there can be no assurance that the FDA will be satisfied with our response to the warning letter or our proposed resolution of the outstanding issues. Until the items raised in the warning
letter are fully corrected, we may be subject to additional regulatory action by the FDA, including the issuance of additional warning letters, injunction, seizure or recall of products, imposition of
fines or penalties or operating restrictions on our facilities. Such actions could significantly disrupt our ongoing business and operations and have a material adverse impact on our financial
position and operating results.
Foreign Regulation.
We are also subject to regulation in the foreign countries in which we manufacture and market our patient
monitoring, diagnostic
cardiology and anesthesia systems. For example, the commercialization of medical devices in the European Union is regulated under a system that presently requires all medical devices sold in the
European Union to bear the CE markan international symbol of adherence to quality assurance standards. Our manufacturing facilities in Hawthorne, California; Snoqualmie, Washington;
Rottweil, Germany, Johor Bahru, Malaysia; Batam, Indonesia; Hyderabad, India; and Suzhou, China are all certified to the International Organization for Standardization's ISO 13485 standard for
medical device quality management systems. Our Hawthorne, California, Snoqualmie, Washington and Rottweil, Germany facilities are also certified to the requirements of Annex II,
section 3 of the Directive 93/42/EEC on Medical Devices, which allows them to self-certify that manufactured products can bear the CE mark. Further, the implementation of the Restriction
of Hazardous Substance Directive ("ROHS") requires that medical devices shipped into the European Union eliminate targeted ROHS substances effective July 23, 2014.
Coverage and Reimbursement.
Government and private sector initiatives to limit the growth of healthcare costs, including price
regulation and
competitive pricing, coverage and payment policies, comparative effectiveness therapies, technology assessments and managed care arrangements, are continuing in many countries where we do business,
including the United States, Europe and Asia. As a result of these changes, the marketplace has placed increased emphasis on the delivery of more cost-effective medical therapies. In addition, because
there is generally no separate reimbursement from third-party payers to our customers for many of our products, the additional costs associated with the use of our products can impact the profit
margin of our customers. Accordingly, these various initiatives have created increased price sensitivity over healthcare products generally and may impact demand for our products and technologies.
Healthcare
cost containment efforts have also prompted domestic hospitals and other customers of medical devices to consolidate into larger purchasing groups to enhance purchasing power,
and this trend is expected to continue. The medical device industry has also experienced some consolidation, partly in order to offer a broader range of products to large purchasers. As a result,
transactions with customers are larger, more complex and tend to involve more long-term contracts than in the past. These larger customers, due to their enhanced purchasing power, may attempt to
increase the pressure on product pricing.
In
2010, significant reforms to the healthcare system were adopted as law in the United States. Among other things, the Patient Protection and Affordable Care Act, as amended by the
Health Care and Education Reconciliation Act, which we refer to collectively as the Affordable Care Act, requires the medical device industry to subsidize healthcare reform in the form of a 2.3%
excise tax on United States sales of most medical devices, which went into effect in 2013. The Consolidated Appropriations Act, 2016, signed into law in December 2015, includes a two-year moratorium
(January 1, 2016 - December 31, 2017) on the excise tax. It is not clear at this time whether the moratorium will be extended, or what the full impact of the Affordable
Care Act will be.
In
addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into
law, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending
20
Table of Contents
reductions.
The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation's automatic reduction to
several government programs. This includes reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and will stay in effect through 2024, unless
additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 (ATRA) was signed into law which, among other things, further reduced Medicare payments to
several providers, including hospitals and imaging centers. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts
that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressure.
Other Healthcare Laws.
In addition to FDA restrictions on marketing and promotion of drugs and devices, other federal and state
laws restrict our
business practices. These laws include, without limitation, data privacy and security laws, anti-kickback and false claims laws, and transparency laws regarding payments or other items of value
provided to healthcare providers.
As
a participant in the healthcare industry, we are subject to extensive regulations protecting the privacy and security of patient health information that we receive, including the
Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH), which was enacted as part of
the American Recovery and Reinvestment Act of 2009. Among other things, these regulations impose extensive requirements for maintaining the privacy and security of individually identifiable health
information, known as "protected health information." The HIPAA privacy regulations do not preempt state laws and regulations relating to personal information that may also apply to us. Our failure to
comply with these regulations could expose us to civil and criminal sanctions.
The
federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or
rebate), directly or indirectly, overtly or covertly, to induce or in return for the purchasing, leasing, ordering, or arranging for or recommending the purchase, lease or order of items or services
for which payment may be made, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term "remuneration" has been broadly interpreted to include anything of value.
Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Further, a claim
including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.
The
federal False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment or
approval to the federal government, or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim
includes "any request or demand" for money or property presented to the U.S. Government. Medical device manufacturers have been held liable under these laws if they are deemed to cause the submission
of false or fraudulent claims by, for example, providing customers with inaccurate billing or coding information.
The
HIPAA provisions also created federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any
healthcare benefit program, including private third-party payers, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a
healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery
of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statutes or specific intent to violate them
in order to have committed a violation. Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and
21
Table of Contents
may
apply regardless of payer, in addition to items and services reimbursed under Medicaid and other state programs.
These
laws impact the kinds of financial arrangements we may have with hospitals or other potential purchasers of our products. They particularly impact how we structure our sales
offerings, including discount practices, customer support, education and training programs, physician consulting, research grants and other service arrangements. If our operations are found to be in
violation of any of the health regulatory laws described above or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal and civil and
administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, contractual damages, reputational harm, and the curtailment or
restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.
Additionally,
there has been a recent trend of increased federal and state regulation of payments and other transfers of value provided to healthcare professionals or entities. The
federal Physician Payment Sunshine Act requires that certain device manufacturers track and report to the government information regarding payments and other transfers of value to physicians and
teaching hospitals, as well as ownership and investment interests held by physicians and their family members. A manufacturer's failure to submit timely, accurately and completely the required
information for all payments, transfers of value or ownership or investment interests may result in civil monetary penalties of up to an aggregate of $150,000 per year, and up to an aggregate of
$1 million per year for "knowing failures." Certain states also mandate implementation of compliance programs, impose restrictions on device manufacturer marketing practices and/or require the
tracking and reporting of gifts, compensation and other remuneration to healthcare professionals and entities.
We
are subject to similar laws in foreign countries where we conduct business. For example, within the European Union, the control of unlawful marketing activities is a matter of
national law in each of the member states. The member states of the European Union closely monitor perceived unlawful marketing activity by companies. We could face civil, criminal and administrative
sanctions if any member state determines that we have breached our obligations under its national laws. Industry associations also closely monitor the activities of member companies. If these
organizations or authorities name us as having breached our obligations under their regulations, rules or standards, our reputation would suffer and our business and financial condition could be
adversely affected.
Environmental Regulations
We are subject to various environmental laws, directives, and regulations pertaining to the use, storage, handling and disposal of
hazardous substances used, and hazardous wastes generated, in the manufacture of our products. Such laws mandate the use of controls and practices designed to mitigate the impact of our operations on
the environment, and under such laws we may be held liable for the costs associated with the remediation and removal of any unintended or previously unknown releases of hazardous substances on,
beneath or from our property and associated operations, including the remediation of hazardous waste disposed off-site. Such laws may impose liability without regard to whether we knew of, or caused,
the release of such hazardous substances. Any failure by us to comply with present or future regulations could subject us to the imposition of substantial fines, suspension of production, alteration
of manufacturing processes or cessation of operations, any of which could have a material adverse effect on our business, financial condition and results of operations.
We
believe that, except to an extent that would not have a material adverse effect on our business, financial condition or results of operations, we are currently in compliance with all
environmental regulations in connection with our manufacturing operations, and that we have obtained all environmental permits necessary to conduct our business. The amount of hazardous substances
used, and hazardous wastes generated, by us may increase in the future depending on changes in our operations. To ensure compliance and practice proper due diligence, we conduct appropriate
environmental audits and investigations at our manufacturing facilities in North America, Asia Pacific, and Europe, and, to the extent practicable, on all new properties. Our manufacturing facilities
conduct
22
Table of Contents
regular
internal audits to ensure proper environmental permits and controls are in place to meet changes in operations. Third-party investigations address matters related to current and former
occupants and operations, historical land use, and regulatory oversight and status of associated properties and/or operations (including surrounding properties). The purpose of these studies is to
identify, as of the date of such report, potential areas of environmental concern related to past and present activities or from nearby operations. The scope and extent of each investigation is
dependent upon the size and complexity of the property and/or operation and on recommendations by independent environmental consultants.
During
one such investigation at our Hawthorne, California facility, we discovered soil and groundwater contamination that we believe was the result of unspecified on- and off-site
releases occurring prior to our occupancy. Historical usage of this site includes semiconductor and electronics manufacturing, dating back to the mid-1960s, as well as possible aircraft and related
manufacturing dating back to the early 1940s. Similar operations, including chemical manufacturing and storage, were conducted at neighboring sites throughout that period and into the 1990s. It is not
presently known when the releases occurred or by whom they were
caused, though our records, in conjunction with data obtained from soil and groundwater surveys, support our assertion that these releases are historical in nature. The groundwater contamination is a
known regional issue, not limited to our premises or our immediate surroundings. We filed the requisite reports concerning this site with the appropriate environmental authorities upon discovery, and
in cooperation with the local governing agency, have provided additional historical information and conducted further site characterization studies. Recent activities include the installation of
groundwater monitoring wells, indoor air quality monitoring and additional soil and soil vapor studies. Results from these studies are being evaluated to determine the extent of the on-site releases
as well as appropriate and cost-effective remedial action measures. Periodic groundwater monitoring is expected to continue until such time as the governing authority requests further action.
Competition
The markets in which we operate are highly competitive and characterized by evolving customer needs and rapid technological change. We
compete with a number of other manufacturers, some of which have significantly greater financial, technical and marketing resources than we have. In addition, these competitors may have the ability to
respond more quickly to new or emerging technologies, adapt more quickly to changes in customer requirements, have stronger customer relationships, have greater name recognition and devote greater
resources to the development, promotion and sale of their products than we do. As a result, we may not be able to compete successfully against designers and manufacturers of specialized electronic
systems and components or within the markets for security and inspection systems, patient monitoring, diagnostic cardiology, anesthesia systems and defibrillator products or optoelectronic devices.
Future competitive pressures may materially and adversely affect our business, financial condition and results of operations.
In
the security and inspection market, competition is based primarily on factors such as product performance, functionality and quality, government regulatory approvals and
qualifications, the overall cost effectiveness of the system, prior customer relationships, technological capabilities of the products, price, local market presence and breadth of sales and service
organization. We believe that our principal competitors in the market for security and inspection products are Smiths Detection; L-3 CommunicationsSecurity and Detection Systems division;
American Science and Engineering; Morpho Detection; Leidos; CEIA; Gilardoni, Nuctech and Astrophysics. Competition could result in price reductions, reduced margins and loss of market share. Although
our competitors offer products in competition with one or more of our products, we can supply a variety of system types and offer among the widest array of solutions available from a single supplier.
This variety of technologies also permits us to offer unique hybrid systems to our customers that utilize two or more of these technologies, thereby optimizing flexibility, performance and cost to
meet the customer's unique application requirements.
In
the patient monitoring, diagnostic cardiology, anesthesia systems delivery and defibrillator market, competition is also based on a variety of factors including product performance,
functionality, value and breadth of
23
Table of Contents
sales
and service organization. We believe that our principal competitors in the market for patient monitoring, diagnostic cardiology, anesthesia systems and related supplies are Philips Healthcare;
GE Healthcare; Mindray Medical; Mortara Instrument; Dräger Medical; Nihon Kohden; Penlon, Maquet and Welch Allyn. We believe that our principal competitors in the market for our
defibrillator products are Koninklijke Philips N.V., Zoll Medical Corporation, Physio-Control, Inc. and Cardiac Science. Competition could result in price reductions, reduced margins and
loss of our market share. We believe that our patient monitoring products are easier to use than the products of many of our competitors because we offer a consistent user interface throughout many of
our product lines. We also believe that the capability of our monitoring systems to connect together, and to the hospital IT infrastructure, is a key competitive advantage. Further, while some of our
competitors are also beginning to introduce portal technology, which allows remote access to data from the bedside monitor, central station or other point of care, we believe that our competing
technologies bring valuable, instant access to labs, radiology and charting at the point of care. Additionally, our defibrillator products have the ability to control the amount of current
administered to a patient, which sets our products apart from a number of competitive products.
In
the markets in which we compete to provide optoelectronic devices and electronics manufacturing services, competition is based primarily on such factors as expertise in the design and
development of optoelectronic devices, product quality, timeliness of delivery, price, customer technical support and the ability to provide fully integrated services from application development and
design through production. We believe that our major competitors in the optoelectronic device markets where we provide products and services are Hamamatsu Photonics, First Sensor and Excelitas
Technologies. Because we specialize in custom subsystems requiring a high degree of engineering expertise, we believe that we generally do not compete to any significant degree with any other large
United States, European or Asian manufacturers of standard optoelectronic components. Competition in the extensive electronic manufacturing services market ranges from multinational corporations with
sales in excess of several billions of dollars, to large regional competitors and to small local assembly companies. In our experience, the OEM customers to whom we provide such services prefer to
engage companies that offer both local and lower-cost off-shore facilities. We believe that our primary domestic competitors for these services are Flextronics, Benchmark Electronics, Plexus, Qual
Pro, ESC and Express Manufacturing Inc. In the United Kingdom, our primary competitors are STI Limited, AsteelFlash and other regional companies. In addition, our high-volume, low-cost contract
manufacturing locations in Southeast Asia compete with other manufacturers in the same region.
Backlog
We currently measure our backlog as quantifiable purchase orders or contracts that have been signed, for which revenues are expected to
be recognized within the next five years. In instances where we are not able to estimate the value of a purchase order or contract they are not included in backlog.
We
ship most of our baggage and parcel inspection, people screening, patient monitoring, diagnostic cardiology and anesthesia systems and optoelectronic devices and value-added
subsystems within one to several months after receiving an order. However, such shipments may be delayed for a variety of reasons, including any special design or requirements of the customer. In
addition, large orders of security and inspection products typically require greater lead-times. Fulfillment of orders of our Rapiscan RTT hold (checked) baggage screening equipment generally requires
longer lead times. Further, we provide turnkey screening services to certain customers for which we may recognize revenue over multi-year periods.
Certain
of our cargo and vehicle inspection systems may require up to a year of lead-time. We have experienced some significant shipping delays associated with our cargo and vehicle
inspection systems. Such delays can occur for many reasons, including: (i) additional time necessary to coordinate and conduct factory inspections with the customer before shipment;
(ii) a customer's need to engage in time-consuming special site preparation to accommodate the system, over which we have no control or responsibility; (iii) additional fine tuning of
such systems once they are installed; (iv) design or specification changes by the customer; (v) time needed to obtain export licenses and/or letters of credit; and (vi) delays
originating from other contractors on the project.
24
Table of Contents
As
of June 30, 2016, our consolidated backlog totaled approximately $623 million, compared to approximately $638 million as of June 30, 2015. Approximately
$163 million of our backlog as of June 30, 2016 is not reasonably expected to be fulfilled in fiscal year 2017. This backlog includes the large turnkey security screening program in
Mexico that we were awarded in fiscal 2012. As the revenue generated from this program is recognized, the corresponding backlog decreases. Sales orders underlying our backlog are firm orders;
although, from time to time we may agree to permit a customer to cancel an order or an order may be cancelled for other reasons. Variations in the size of orders, product mix, or delivery
requirements, among other factors, may result in substantial fluctuations in backlog from period to period. Backlog as of any particular date should not be relied upon as indicative of our revenues
for any future period and cannot be considered a meaningful indicator of our performance on an annual or quarterly basis.
Employees
As of June 30, 2016, we employed approximately 5,847 people, of whom 3,287 were employed in manufacturing, 421 were employed in
engineering or research and development, 543 were employed in administration, 376 were employed in sales and marketing and 1,220 were employed in service capacities. Of the total employees, 2,064 were
employed in the Americas, 2,964 were employed in Asia and 819 were employed in Europe. Many of our employees in Europe have statutory collective bargaining rights. We have never experienced a work
stoppage or strike, and management believes that our relations with our employees are good.
Available Information
We are subject to the informational requirements of the Exchange Act. Therefore, we file periodic reports, proxy statements and other
information with the Securities and Exchange Commission. Such reports, proxy statements and other information may be obtained by visiting the Public Reference Room of the Securities and Exchange
Commission at 100 F Street, N.E., Washington, D.C. 20549 or by calling the Securities and Exchange Commission at 1-800-SEC-0330. In addition, the Securities and Exchange Commission maintains an
internet website (http://www.sec.gov) that contains reports, proxy statements and other information that issuers are required to file electronically.
Our
internet address is: http://www.osi-systems.com. The information found on, or otherwise accessible through, our website is not incorporated into, and does not form a part of
this annual report on Form 10-K or any other report or document we file with or furnish to the Securities and Exchange Commission. We make available, free of charge through our internet
website, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, amendments to those reports filed or furnished pursuant to
Section 13(a) or 15(d) of the Exchange Act, and reports filed pursuant to Section 16 of the Exchange Act, as soon as reasonably practicable after electronically filing such material
with, or furnishing it to, the Securities and Exchange Commission. Also available on our website free of charge are our Corporate Governance Guidelines, the Charters of our Nominating and Governance,
Audit, Compensation and Executive Committees of our Board of Directors and our Code of Ethics and Conduct (which applies to all Directors and employees, including our principal executive officer,
principal financial officer and principal accounting officer). A copy of this annual report on Form 10-K is available without charge upon written request addressed to: c/o Secretary, OSI
Systems, Inc., 12525 Chadron Avenue, Hawthorne, CA 90250 or by calling telephone number (310) 978-0516.
ITEM 1A. RISK FACTORS
Set forth below and elsewhere in this report and in other documents we file with the Securities and Exchange Commission are
descriptions of the risks and uncertainties that could cause our actual results to differ materially from the results contemplated by the forward-looking statements contained in this report. We
encourage you to carefully consider all such risk factors when making investment decisions regarding our company. If any such risks,
25
Table of Contents
or
any other risks that we do not currently consider to be material, or which are not known to us, materialize, our business, financial condition and operating results could be materially adversely
affected.
Fluctuations in our operating results may cause our stock price to decline.
Given the nature of the markets in which we participate, it is difficult to reliably predict future revenues and profitability. Changes
in competitive, market and economic conditions may cause us to adjust our operations. A high proportion of our costs are fixed, due in part to our significant sales, research and development and
manufacturing costs. Thus, small declines in revenue could disproportionately affect our operating results. Factors that may affect our operating results and/or the market price of our Common Stock
include, but are not limited to:
-
-
demand for and market acceptance of our products;
-
-
competitive pressures resulting in lower selling prices;
-
-
adverse changes in the level of economic activity in regions in which we do business;
-
-
low or fluctuating levels of political stability in regions in which we do business;
-
-
adverse changes in industries on which we are particularly dependent;
-
-
changes in the portions of our revenue represented by various products and customers;
-
-
delays or problems in the introduction of new products;
-
-
announcements or introductions of new products, services or technological innovations by our competitors;
-
-
variations in our product mix;
-
-
timing and amount of our expenditures in anticipation of future sales;
-
-
availability of equity and credit markets to provide our customers with funding to make equipment purchases;
-
-
public guidance that we provide regarding future financial results based on facts, judgments and assumptions made at the time of the
publication of the guidance, all of which may change after the publication of the guidance;
-
-
negative resolutions of the matters raised in the warning letter issued in August 2014 by the FDA to our Healthcare division, or
additional actions by or requests from the FDA and unanticipated costs or delays associated with the resolution of these matters;
-
-
adverse outcomes in our litigation matters;
-
-
exchange rate fluctuations;
-
-
increased costs of raw materials or supplies;
-
-
changes in the volume or timing of product orders;
-
-
timing of completion of acceptance testing of some of our products;
-
-
changes in regulatory requirements;
-
-
natural disasters; and
-
-
changes in general economic factors.
Unfavorable currency exchange rate fluctuations could adversely affect our financial results.
Our international sales and our operations in foreign countries expose us to risks associated with fluctuating currency values and
exchange rates. Gains and losses on the conversion of accounts receivable, accounts payable and other monetary assets and liabilities to U.S. dollars may contribute to fluctuations in our results of
operations. In addition, since we conduct business in currencies other than the U.S. dollar but report our financial results in U.S. dollars, increases or decreases in the value of the U.S. dollar
relative to other currencies could have an adverse effect on our results of operations.
26
Table of Contents
We face aggressive competition in each of our operating divisions. If we do not compete effectively, our business will be harmed.
We encounter aggressive competition from numerous competitors in each of our divisions. In the security and inspection and patient
monitoring, cardiology and anesthesia systems markets, competition is based primarily on such factors as product performance, functionality and quality, cost, prior customer relationships,
technological capabilities of the product, price, certification by government authorities, past performance, local market presence and breadth of sales and service organization. In the optoelectronic
devices and electronics manufacturing markets, competition is based primarily on factors such as expertise in the design and development of optoelectronic devices, product quality, timeliness of
delivery, price, customer technical support and on the ability to provide fully-integrated services from application development and
design through volume subsystem production. We may not be able to compete effectively with all of our competitors. To remain competitive, we must develop new products and enhance our existing products
and services in a timely manner. We anticipate that we may have to adjust the prices of many of our products to stay competitive. In addition, new competitors may emerge and entire product lines or
service offerings may be threatened by new technologies or market trends that reduce the value of these product lines or service offerings.
The September 11, 2001 terrorist attacks, subsequent attacks in other locations worldwide and the creation of the U.S. Department of Homeland Security have increased
financial expectations that may not materialize.
The September 11, 2001 terrorist attacks and subsequent attacks in other locations worldwide have created increased interest in
our security and inspection systems and service offerings. However, we are not certain whether the level of demand will continue to be as high as it is now. We do not know what solutions will continue
to be adopted by the U.S. Department of Homeland Security, the U.S. Department of Defense, and similar agencies in other countries and whether our products will be a part of those solutions.
Additionally, should our products and services be considered as a part of future security solutions, it is unclear what the demand for our products and services may be and how quickly funding to
purchase our products and services may be made available. These factors may adversely impact us and create unpredictability in revenues and operating results.
If operators of, or algorithms installed in, our security and inspection systems fail to detect weapons, explosives or other devices or materials that are used to commit a
terrorist act, we could be exposed to product and professional liability and related claims for which we may not have adequate insurance coverage.
Our business exposes us to potential product liability risks that are inherent in the development, manufacturing, sale and service of
security and inspection systems as well as in the provision of training to our customers in the use and operation of such systems. Our customers use our security and inspection systems to help them
detect items that could be used in performing terrorist acts or other crimes. Some of our security and inspection systems require that an operator interpret an image of suspicious items within a bag,
parcel, container or other vessel. Others signal to the operator that further investigation is required. In either case, the training, reliability and competence of the customer's operator are crucial
to the detection of suspicious items.
Security
inspection systems that signal to the operator that further investigation is required are sometimes referred to in the security industry as "automatic" detection systems. Such
systems utilize software algorithms (often designed to meet government requirements) to interpret data produced by the system and to signal to the operator when a dangerous object may be present. Such
algorithms are probabilistic in nature and are also subject to significant technical limitations. Nevertheless, if such a system were to fail to signal to an operator when an explosive or other
contraband was in fact present, resulting in significant damage, we could become the subject of significant product liability claims.
Furthermore,
security inspection by technological means is circumstance and application-specific. Our security and inspection systems are not designed to work under all circumstances and
can malfunction.
27
Table of Contents
We
also offer turnkey security screening solutions under which we perform certain of the security screening tasks that have historically been performed by our customers. Such tasks
include: design, layout and construction of the security checkpoint where the inspection equipment is located; selection of the security equipment to be used at the checkpoint; selection, training and
management of the personnel operating the checkpoint; operation of the security screening equipment; interpretation of the images and other signals produced by the security screening equipment;
maintenance and security of the checkpoint as well as other related services. Such projects expose us to certain professional liability risks that are inherent in performing security inspection
services (in live checkpoint environments and over extended periods of time) for the purpose of assisting our customers in the detection of contraband items, including items that could be used in
performing terrorist acts or other crimes. If a contraband item were to pass through the checkpoint and be used to perform a terrorist act or other crime, we could become the subject of significant
professional liability claims.
In
addition, there are also many other factors beyond our control that could lead to liability claims should an act of terrorism occur. Past terrorism attacks in the U.S. and in other
locations worldwide and the potential for future attacks have caused commercial insurance for such threats to become extremely difficult to obtain. Although we have been able to obtain insurance
coverage, it is likely that, should we be found liable following a major act of terrorism, the insurance we currently have in place would not fully cover the claims for damages.
The Support Anti-terrorism by Fostering Effective Technologies Act of 2002 (SAFETY Act) may not shield us against all legal claims we may face following an act of terrorism.
The SAFETY Act provides important legal liability protections for providers of qualified anti-terrorism products and services. Under
the SAFETY Act, providers, such as our Security division, may apply to the U.S. Department of Homeland Security for coverage of the products and services. If granted coverage, such providers would
receive certain legal protections against product liability, professional liability and certain other claims that could arise following an act of terrorism.
We
have applied to the U.S. Department of Homeland Security for many of the products and services offered by our Security division but we do not enjoy coverage (or the highest level of
coverage) for every product
line, model number and service offering that our Security division provides. In addition, the terms of the SAFETY Act coverage decisions awarded to us by the U.S. Department of Homeland Security
contain conditions and requirements that we may not (or may not be able to) continue to satisfy in the future.
In
the future, if we fail to maintain the coverage that we currently enjoy or fail to timely apply for coverage for new products and services as we introduce them, or if the U.S.
Department of Homeland Security limits the scope of any coverage previously awarded to us, denies us coverage or continued coverage for a particular product, product line or service offering, or
delays in making decisions about whether to grant us coverage, we may become exposed to legal claims that the SAFETY Act was otherwise designed to prevent.
The
SAFETY Act was not designed to shield providers of qualified anti-terrorism products and services from all types of claims that may arise from acts of terrorism, including from many
types of claims lodged in courts outside of the United States or acts of terrorism that occur outside of the United States. This too could leave us exposed to significant legal claims and litigation
defense costs despite the SAFETY Act awards we have received.
Our insurance coverage may be inadequate to cover all significant risk exposures.
We are exposed to liabilities that are unique to the products and services we provide. We maintain insurance for certain risks, and we
believe our insurance coverage is consistent with general practices within our industry. However, the amount of our insurance coverage may not cover all claims or liabilities and we may be forced to
bear substantial costs. While some of our products are shielded from liability within the U.S. under the SAFETY Act, no
28
Table of Contents
such
protection is available outside the U.S., potentially resulting in significant liabilities. The amount of insurance coverage we maintain may be inadequate to cover these or other claims or
liabilities.
Our patient monitoring, cardiology and anesthesia systems could give rise to product liability claims and product recall events that could materially and adversely affect
our financial condition and results of operations.
The development, manufacturing and sale of medical devices expose us to significant risk of product liability claims, product recalls
and, sometimes, product failure claims. We face an inherent business risk of financial exposure to product liability claims if the use of our medical devices results in personal injury or death.
Substantial product liability litigation currently exists within the medical device industry. Some of our patient monitoring, cardiology and anesthesia systems products may become subject to product
liability claims and/or product recalls. Future product liability claims and/or product recall costs may exceed the limits of our insurance coverages or such insurance may not continue to be available
to us on commercially reasonable terms, or at all. In addition, a significant product liability claim or product recall could significantly damage our reputation for producing safe, reliable and
effective products, making it more difficult for us to market and sell our products in the future. Consequently, a product liability claim, product recall or other claim could have a material adverse
effect on our business, financial condition, operating results and cash flows.
If we are unable to sustain high-quality processes for the manufacture and delivery of goods and services, our reputation could be harmed, our competitive advantage could
erode and we could incur significant costs.
Quality is extremely important to us and our customers, due in part to the serious consequences of product failure. Our quality
certifications are critical both to the marketing success of our goods and services and to the satisfaction of both regulatory and contractual requirements under which we sell many of our products. If
we fail to meet these standards or other standards required in our industries, we could lose customers and market share, our revenue could decline and we could face significant costs and other
liabilities.
As a U.S. Government contractor, we are subject to extensive Federal procurement rules and regulations as well as contractual obligations that are unique to doing business
with the U.S. Government. Non-compliance with any such rules, regulations or contractual obligations could negatively affect current programs, potential awards and our ability to do business with the
U.S. Government in the future.
U.S. Government contractors must comply with extensive procurement regulations and other requirements including, but not limited to,
those appearing in the Federal Acquisition Regulation (FAR) and its supplements, as well as specific procurement rules and contractual conditions imposed by various U.S. Government agencies. Many of
these types of requirements do not appear in our contracts with commercial customers or foreign governments. In particular, government contracts typically contain provisions and are subject to laws
and regulations that give the government agencies rights and
remedies not typically found in commercial contracts, including providing the government agency with the ability to unilaterally:
-
-
terminate our existing contracts;
-
-
reduce the value of our existing contracts;
-
-
modify some of the terms and conditions in our existing contracts;
-
-
suspend or permanently prohibit us from doing business with the government or with any specific government agency;
-
-
control and potentially prohibit the export of our products;
-
-
cancel or delay existing multiyear contracts and related orders if the necessary funds for contract performance for any subsequent
year are not appropriated;
-
-
decline to exercise an option to extend an existing multiyear contract; and
29
Table of Contents
-
-
claim rights in technologies and systems invented, developed or produced by us.
U.S.
Government agencies and some other agencies with which we contract can terminate their contracts with us for convenience, and in that event we generally may recover only our
incurred or committed costs, settlement expenses and profit on the work completed prior to termination. If an agency terminates a contract with us for default, we may be denied any recovery and may be
liable for excess costs incurred by the agency in procuring undelivered items from an alternative source. We may receive notices under such contracts that, if not addressed to the agency's
satisfaction, could give the agency the right to terminate those contracts for default or to cease procuring our services under those contracts. The U.S. Government or regulatory agencies may initiate
civil False Claims Act litigation against us based on allegations related to our performance of contracts for the U.S. Government, which can be expensive to defend and if found liable can result in
treble damages and significant civil penalties. The U.S. Government may also initiate administrative proceedings that, if resulting in an adverse finding against us or our subsidiaries as to our
present responsibility to be a U.S. Government contractor or subcontractor, could result in our company or our subsidiaries being suspended for a period of time from eligibility for awards of new
government contracts or task orders or in a loss of export privileges and, if satisfying the requisite level of seriousness, in our debarment from contracting with the U.S. Government for a specified
term as well as being subject to other remedies available to the U.S. Government.
For
example, subsidiaries within our Security division received a "show cause" letter in November 2012 from the U.S. Transportation Security Administration and a related Notice for
Proposed Debarment from the U.S. Department of Homeland Security in May 2013. Although, with respect to that "show cause" letter and Notice for Proposed Debarment, we were ultimately able to reach an
Administrative Agreement with the U.S. Government, which allowed us to continue with our current and future business with U.S. Government agencies, there is no assurance that we would be able to reach
a similar outcome with respect to any future proceedings that we may become involved. In addition, if our Security division fails to remain in compliance with its current Administrative Agreement, the
U.S. Department of Homeland Security could initiate debarment proceedings.
The loss of certain of our customers, including government agencies that can modify or terminate agreements more easily than other commercial customers with which we
contract, the failure to continue to diversify our customer base or the non-renewal of certain material contracts could have a negative effect on our reputation and could have a material adverse
effect on our business, financial condition and results of operations.
We sell many of our products to prominent, well-respected institutions, including agencies and departments of the U.S. Government,
state and local governments, foreign governments, renowned hospitals and hospital networks, and large military-defense and space-industry contractors. Many of these larger customers spend considerable
resources testing and evaluating our products and our design and manufacturing processes and services. Some of our smaller customers know this and rely on this as an indication of the high-quality and
reliability of our products and services. As a result, part of our reputation and success depends on our ability to continue to sell to larger institutions that are known for demanding high standards
of excellence.
The
loss or termination of a contract by such an institution, even if for reasons unrelated to the quality of our products or services, could therefore have a more wide-spread and
potentially material adverse effect on our business, financial condition and results of operations.
Further,
we are generating revenues from certain customers, the loss of which could have a material adverse effect on our business. In particular, in fiscal 2012, we entered into a
six-year contract with the Mexican government to provide a turnkey security screening solution at various locations throughout the country. This project is expected to provide significant revenues
over the life of the contract. The termination, non-renewal or reduction in scope of this contract, even if for reasons unrelated to the quality of our products or services, could therefore have a
more wide-spread and potentially material adverse effect on our business, financial condition and
30
Table of Contents
results
of operations, including, but not limited to, impairment of capital assets purchased or manufactured specifically for this contract.
Our revenues are dependent on orders of security and inspection systems, turnkey security screening solutions and patient monitoring, cardiology and anesthesia systems,
which may have lengthy and unpredictable sales cycles.
Sales of security and inspection systems and turnkey security screening solutions often depend upon the decision of governmental
agencies to upgrade or expand existing airports, border crossing inspection sites, seaport inspection sites, military facilities and other security installations. In the case of turnkey security
screening solutions, the commencement of screening operations may be dependent on the approval, by a government agency, of the protocols and procedures that our personnel are to follow during the
performance of their activities. Sales outside of the United States of our patient monitoring, diagnostic cardiology and anesthesia systems depend in significant part on the decision of governmental
agencies to build new medical facilities or to expand or update existing medical facilities. Accordingly, a significant portion of our sales of security and inspection systems, turnkey security
screening solutions and our patient monitoring, diagnostic cardiology and anesthesia systems is often subject to delays associated with the lengthy approval processes. During these approval periods,
we expend significant financial and management resources in anticipation of future revenues that may not occur. If we fail to receive such revenues after expending such resources, such failure could
have a material adverse effect on our business, financial condition and results of operations.
U.S and foreign budget control provisions could reduce government spending, which could adversely impact our revenues, earnings, cash flows and financial condition.
In August 2011, Congress enacted the Budget Control Act of 2011 (BCA), committing the U.S. Government to significantly reduce the
federal deficit over ten years. The BCA contains provisions commonly referred to as "sequestration", which call for substantial, unspecified automatic spending cuts split between defense and
non-defense programs that may continue for a period of ten years. The BCA also included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and
will stay in effect through 2024, unless additional Congressional action is taken. Likewise, various European governments have implemented or intend to implement austerity measures intended to reduce
government spending. Such measures may reduce demand for our products directly by affected governmental agencies and by our customers who derive revenues from these governmental agencies or
governmental healthcare programs. We cannot currently predict the impact of governmental spending reductions on us or our customers or whether and to what extent our business and results of operations
may be adversely harmed.
If we fail to perform on our existing agreements to provide security screening solutions to customers after expending substantial resources, such failure could have a
material adverse effect on our business, financial condition and results of operations.
Certain of our projects require the expenditure of substantial management and financial resources in anticipation of future revenue
generation. For example, in 2012, we entered into a
substantial six-year contract with the Mexican government to provide a turnkey security screening solution at various sites throughout Mexico, which required substantial expenditures for capital
equipment and infrastructure. Although to date we have generated revenues from this project, if we fail to perform and thus don't receive continued revenues over the remaining life of the project
after expending such resources, such failure could have a material adverse effect on our business, financial condition and results of operations. We anticipate that future contracts for turnkey
security screening solutions in other territories could also require the outlay and management of substantial financial resources for capital equipment and infrastructure.
31
Table of Contents
Turnkey
screening solutions projects, in contrast to the sale and installation of security inspection equipment, also require that we hire and manage large numbers of local personnel in
jurisdictions where we may not have previously operated. They also require that we establish, adhere to, adapt and monitor operating procedures over periods that last much longer than our other
projects. If we are unable to efficiently manage the adaptation and growth of our operations relating to these projects, our operations could be materially and adversely affected.
If we do not introduce new products in a timely manner, our products could become obsolete and our operating results would suffer.
We sell many of our products in industries characterized by rapid technological changes, frequent new product and service introductions
and evolving industry standards and customer needs. Without the timely introduction of new products and enhancements, our products could become technologically obsolete over time, in which case our
revenue and operating results would suffer. The success of our new product offerings will depend upon several factors, including our ability to:
-
-
accurately anticipate customer needs;
-
-
innovate and develop new technologies and applications;
-
-
successfully commercialize new technologies in a timely manner;
-
-
price our products competitively and manufacture and deliver our products in sufficient volumes and on time; and
-
-
differentiate our offerings from our competitors' offerings.
Some
of our products are used by our customers to develop, test and manufacture their products. We therefore must anticipate industry trends and develop products in advance of the
commercialization of our customers' products. In developing any new product, we may be required to make a substantial investment before we can determine the commercial viability of the new product. If
we fail to accurately foresee our customers' needs and future activities, we may invest heavily in research and development of products that do not lead to significant revenues.
Interruptions in our ability to purchase raw materials and subcomponents may adversely affect our profitability.
We purchase raw materials and certain subcomponents from third parties. Standard purchase order terms are as long as one year at fixed
costs, but we do not have guaranteed long-term supply arrangements with our suppliers. In addition, for certain raw materials and subcomponents that we use, there are a limited number of potential
suppliers that we have qualified or that we are currently able to qualify. Consequently, some of the key raw materials and subcomponents that we use are currently available to us only from a single
vendor. The reliance on a single qualified vendor could result in delays in delivering products or increases in the cost of manufacturing the affected products. Any material interruption in our
ability to purchase necessary raw materials or subcomponents could adversely affect our ability to fulfill customer orders and therefore could ultimately have a material adverse effect on our
business, financial condition and results of operations.
Delays by the construction firms we engage may interfere with our ability to complete projects on time.
Purchasers of our security and inspection systems and turnkey security screening solutions sometimes require, as a part of our
contract, the construction of the facilities that will house our systems and/or operations. Some of these construction projects are significant in size and complexity. We engage qualified construction
firms to perform this work. However, if such firms experience delays, if they perform sub-standard work or if we fail to properly monitor the quality of their work or the timeliness of their progress,
we may not be able to complete our construction projects on time. In any such circumstance, we could face the imposition of delay penalties and breach
32
Table of Contents
of
contract claims by our customer. In addition, we could be forced to incur significant expenses to rectify the problems caused by the construction firm. Any material delay caused by our construction
firm subcontractors could therefore ultimately have a material adverse effect on our business, financial condition and results of operations.
We contract with third party service vendors who may be unable to fulfill contracts on time.
We contract with third-party vendors to service our equipment in the field. We have made such arrangements because sometimes it is more
efficient to outsource these activities than it is for our own employees to service our equipment. In addition, some of these vendors maintain stocks of spare parts that are more efficiently accessed
in conjunction with a service agreement than would be the case if we were to maintain such spare parts independently. Any material interruption in the ability of our vendors to fulfill such service
contracts could adversely affect our ability to fulfill customer orders and therefore could ultimately have a material adverse effect on our business, financial condition and results of operations.
We have the potential to accumulate excess inventory.
Because of long lead times and specialized product designs, in certain cases we purchase components and manufacture products in
anticipation of customer orders based on customer forecasts. For a variety of reasons, such as decreased end-user demand for our products, inadequate or inaccurate forecasts, or other issues that
might impact production planning, our customers might not purchase
all the products that we have manufactured or for which we have purchased components. In any such event, we would attempt to recoup material and manufacturing costs by means such as returning
components to our vendors, disposing of excess inventory through other channels, or requiring our OEM customers to purchase or otherwise compensate us for such excess inventory. However, some of our
significant customer agreements do not give us the ability to require our OEM customers to do this. To the extent that we are unsuccessful in recouping our material and manufacturing costs, this could
adversely affect our ability to fulfill customer orders and therefore could ultimately have a material adverse effect on our business, financial condition and results of operations. In addition,
because of the complex customer acceptance criteria associated with some of our products, on some occasions, products whose title has passed to our customers are still included in our inventory until
revenue recognition criteria is met. As a result, inventory levels may be inflated from time to time.
We may not be able to successfully implement our acquisitions and investment strategies, integrate acquired businesses into our existing business or make acquired businesses
profitable.
One of our strategies is to supplement our internal growth by acquiring and investing in businesses and technologies that complement or
augment our existing product lines. This growth has placed, and may continue to place, significant demands on our management, working capital and financial resources. We may be unable to identify or
complete promising acquisitions for many reasons, including:
-
-
competition among buyers;
-
-
the need for regulatory approvals, including antitrust approvals; and
-
-
the high valuations of businesses.
Some
of the businesses we may seek to acquire or invest in may be marginally profitable or unprofitable. For these businesses to achieve acceptable levels of profitability, we must
improve their management, operations, products and market penetration. We may not be successful in this regard and we may encounter other difficulties in integrating acquired businesses into our
existing operations.
To
finance our acquisitions, we may have to raise additional funds, through either public or private financings. We may be unable to obtain such funds or may be able to do so only on
unfavorable terms.
33
Table of Contents
Our acquisition and alliance activities could disrupt our ongoing business.
We intend to continue to make investments in companies, products and technologies, either through acquisitions, investments or
alliances. Acquisition and alliance activities often involve risks, including:
-
-
difficulty in assimilating the acquired operations and employees and realizing synergies expected to result from the acquisition;
-
-
difficulty in managing product co-development activities with our alliance partners;
-
-
difficulty in effectively coordinating sales and marketing efforts;
-
-
difficulty in combining product offerings and product lines quickly and effectively;
-
-
difficulty in retaining the key employees of the acquired operation;
-
-
disruption of our ongoing business, including diversion of management time;
-
-
inability to successfully integrate the acquired technologies and operations into our businesses and maintain uniform standards,
controls, policies and procedures;
-
-
lacking the experience necessary to enter into new product or technology markets successfully; and
-
-
difficulty in integrating financial reporting systems and implementing controls, procedures and policies, including disclosure
controls and procedures and internal control over financial reporting, appropriate for public companies of our size at companies that, prior the acquisition, had lacked such controls, procedures and
policies.
Integrating
acquired businesses has been and will continue to be complex, time consuming and expensive, and can negatively impact the effectiveness of our internal control over financial
reporting. The use of debt to fund acquisitions or for other related purposes increases our interest expense and leverage. If we issue equity securities as consideration in an acquisition, current
stockholders percentage ownership and earnings per share may be diluted. As a result of these and other risks, we cannot be certain that our previous or future acquisitions will be successful and will
not materially adversely affect the conduct, operating results or financial condition of our business.
Our ability to successfully adapt to ongoing organizational changes could impact our business results.
We have executed a number of significant business and organizational changes to rationalize our overall cost structure. These changes
have included and may continue to include the implementation of cost-cutting measures and the consolidation of facilities. We expect these types of changes may continue from time to time in the future
as we uncover additional opportunities to streamline our operations. Successfully managing these changes is critical to our productivity improvement and business success. If we are unable to
successfully manage these changes, while continuing to invest in business growth, our financial results could be adversely impacted.
Economic, political, legal, operational and other risks associated with international sales and operations could adversely affect our financial performance.
In fiscal 2014, 2015 and 2016 revenues from shipments made to customers outside of the United States accounted for approximately 61%,
57% and 64% of our revenues, respectively. Since we sell certain of our products and services worldwide, our businesses are subject to risks associated with doing business internationally. We
anticipate that revenues from international operations will continue to represent a substantial portion of our total revenue. In addition, many of our manufacturing facilities, and therefore
employees, suppliers, real property, capital equipment, cash and other assets are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including
without limitation:
-
-
changes in foreign currency exchange rates;
34
Table of Contents
-
-
changes in a country's or region's political or economic conditions, particularly in developing or emerging markets;
-
-
political and economic instability, including the possibility of civil unrest, terrorism, mass violence or armed conflict;
-
-
longer payment cycles of foreign customers and difficulty of collecting receivables in foreign jurisdictions;
-
-
trade protection measures;
-
-
difficulty in staffing and managing widespread operations;
-
-
difficulty in managing distributors and sales agents and their compliance with applicable laws;
-
-
changes in a foreign government's budget, leadership and national priorities;
-
-
increased legal risks arising from differing legal systems; and
-
-
compliance with export control and anticorruption legislation, including but not limited to, the Foreign Corrupt Practices Act and UK
Bribery Act and International Traffic in Arms Regulations.
-
-
On June 23, 2016, the United Kingdom (U.K.) held a referendum in which voters approved an exit from the European Union (E.U.),
commonly referred to as "Brexit". There is substantial uncertainty surrounding the Brexit vote and any impact of Brexit depends on the terms of the UK's withdrawal from the EU, which still need to be
determined and could take several years to accomplish. The UK's withdrawal from the EU could result in a global economic downturn, which could depress the demand for our products and services. The UK
also could lose access to the single EU market and to the global trade deals negotiated by the EU on behalf of its members, depressing trade between the UK and other countries, which would negatively
impact our international operations. Additionally, we may face new regulations regarding trade, security and employees, among others in the UK. Compliance with such regulations could be costly,
negatively impacting our business, results of operations and financial condition.
We are facing an increasingly complex international regulatory environment which is constantly changing and if we fail to comply with international regulatory requirements,
or are unable to comply with changes to such requirements, our financial performance may be harmed.
Our international operations and sales subject us to an international regulatory environment which is becoming increasingly complex and
is constantly changing due to factors beyond our control. Risks associated with our international operations and sales include, without limitation, those arising from the following
factors:
-
-
differing legal and court systems and changes to such systems;
-
-
differing labor laws and changes in those laws;
-
-
differing tax laws and changes in those laws;
-
-
differing environmental laws and changes in those laws;
-
-
differing laws governing our distributors and sales agents and changes in those laws;
-
-
differing protection of intellectual property and changes in that protection; and
-
-
differing import and export requirements and changes to those requirements.
If
we fail to comply with applicable international regulatory requirements, even if such non-compliance by us is inadvertent, or if we are unable to comply with changes to such
requirements, our financial performance may be harmed.
35
Table of Contents
Our global operations expose us to legal compliance risks related to certain anti-bribery and anti-corruption laws.
We are required to comply with the U.S. Foreign Corrupt Practices Act, which prohibits United States companies from engaging in bribery
or making other prohibited payments to foreign officials for the purpose of obtaining or retaining business. It also requires us to maintain specific record-keeping standards and adequate internal
accounting controls. In addition, we are subject to similar requirements in other countries. Bribery, corruption, and trade laws and regulations, and the enforcement thereof, are increasing in
frequency, complexity and severity on a global basis. Although we have internal policies and procedures with the intention of assuring compliance with these laws and regulations, our employees,
distributors, resellers and contractors involved in our international sales may take actions in violations of such policies. If our internal controls and compliance program do not adequately prevent
or
deter our employees, distributors, resellers, contractors and/or other third parties with whom we do business from violating anti-bribery, anti-corruption or similar laws and regulations, we may incur
severe fines, penalties and reputational damage.
We are subject to import and export controls that could subject us to liability or impair our ability to compete in international markets.
Due to the international scope of our operations, we are subject to a complex system of import- and export-related laws and
regulations, including U.S. export control and customs regulations and customs regulations of other countries. These regulations are complex and vary among the legal jurisdictions in which we operate.
Any alleged or actual failure to comply with such regulations may subject us to government scrutiny, investigation, and civil and criminal penalties, and may limit our ability to import or export our
products or to provide services outside the United States. Depending on severity, any of these penalties could have a material impact on our business, financial condition and results of operations.
There are inherent risks associated with operations in Mexico.
We are currently in the process of fulfilling a multi-year agreement to provide a turnkey security scanning solution to the tax and
customs authority of Mexico. This agreement is individually material to our business, financial condition and results of operations. There are certain administrative, legal, governmental and societal
risks to operating in Mexico that could adversely impact our operations. Any one or more of the risks that could adversely affect our ability to fulfill our agreement and therefore ultimately have a
material adverse effect on our business, financial condition and results of operations include, without limitation:
-
-
regional political and economic instability;
-
-
high rate of crime in Mexico where we conduct operations;
-
-
ability of key suppliers and subcontractors to fulfill obligations;
-
-
ability to hire and maintain a significant work force;
-
-
burdensome and evolving government regulations;
-
-
cooperation of various departments of the Mexican government in issuing permits, and inspecting our operations on a timely basis;
-
-
providing adequate security among other items;
-
-
receipt of payments in a timely manner;
-
-
termination or change in scope of program and at the election of the government; and
-
-
change in the value of the Mexican peso.
36
Table of Contents
Our operations are vulnerable to interruption or loss due to natural disasters, epidemics, terrorist acts and other events beyond our control, which could adversely impact
our operations.
Although we perform manufacturing in multiple locations, we generally do not have redundant manufacturing capabilities in place for any
particular product or component. As a result, we depend on our current facilities for the continued operation of our business. A natural disaster, epidemic, terrorist act, act of war, or other natural
or manmade disaster affecting any of our facilities could significantly disrupt our operations, or delay or prevent product manufacturing and shipment for the time required to repair, rebuild, or
replace our manufacturing facilities. This delay could be lengthy and we could incur significant expenses to repair or replace the facilities. Any similar natural or manmade disaster that affects a
key supplier or customer could lead to a similar disruption in our business.
Third parties may claim we are infringing their intellectual property rights, and we could suffer significant litigation or licensing expenses or be prevented from selling
products.
As we introduce any new and potentially promising product or service, or improve existing products or services with new features or
components, companies possessing competing technologies, or other companies owning patents or other intellectual property rights, may be motivated to assert infringement claims in order to generate
royalty revenues, delay or diminish potential sales and challenge our right to market such products or services. Even if successful in defending against such claims, patent and other intellectual
property related litigation is costly and time consuming. In addition, we may find it necessary to initiate litigation in order to protect our patent or other intellectual property rights, and even if
the claims are well-founded and ultimately successful such litigation is typically costly and time-consuming and may expose us to counterclaims, including claims for intellectual property
infringement, anti-trust, or other such claims. Third parties could also obtain patents or other intellectual property rights that may require us to either redesign products or, if possible, negotiate
licenses from such third parties. Adverse determinations in any such litigation could result in significant liabilities to third parties or injunctions, or could require us to seek licenses from third
parties, and if such licenses are not available on commercially reasonable terms, prevent us from manufacturing, importing, distributing, selling or using certain products, any one of which could have
a material adverse effect on us. In addition, some licenses may be non-exclusive, which could provide our competitors access to the same technologies. Under any of these circumstances, we may incur
significant expenses.
Our ongoing success is dependent upon the continued availability of certain key employees.
We are dependent in our operations on the continued availability of the services of our employees, many of whom are individually key to
our current and future success, and the availability of new employees to implement our growth plans. The market for skilled employees is highly competitive, especially for employees in technical
fields. While our compensation programs are intended to attract and retain the employees required for us to be successful, ultimately, we may not be able to retain the services of all of our key
employees or a sufficient number to execute on our plans. In addition, we may not be able to continue to attract new employees as required.
Healthcare cost containment pressures and legislative or regulatory reforms may affect our ability to sell our products profitably.
All third-party payers, whether governmental or commercial, whether inside the United States or outside, are developing increasingly
sophisticated methods of controlling healthcare costs. These cost-control methods also potentially limit the amount that healthcare providers may be willing to pay for medical devices. In the United
States, hospital and other healthcare provider customers, including physicians and ambulatory surgery centers, that purchase our products typically bill various third-party payers to cover all or a
portion of the costs and fees associated with the procedures or tests in which our products are used and bill patients for any deductibles or co-payments. Because there is often no separate
reimbursement for our products, any decline in the amount payers are willing to reimburse our customers for the procedures and tests associated with our products could make it
37
Table of Contents
difficult
for customers to continue using, or adopt, our products and create additional pricing pressure for us. If we are forced to lower the price we charge for our products, our gross margins will
decrease, which will adversely affect our ability to invest in and grow our business.
There
have been, and we expect there will continue to be, a number of legislative and regulatory proposals to change the healthcare system, and some could involve changes that could
significantly affect the ways in which doctors, hospitals, healthcare systems and health insurance companies are compensated for the services they provide, which could have a material impact on our
business. For example, the Affordable Care Act includes a 2.3% excise tax on U.S. sales of a wide range of medical devices. The excise tax became effective in 2013 and increased our costs. Although
the Consolidated Appropriations Act, 2016, signed into law in December 2015, includes a two-year moratorium (January 1, 2016 - December 31, 2017) on the medical device
excise tax, it is not clear at this time whether the moratorium will be extended. Nor is it clear at this time to
what extent the Affordable Care Act may impact the ability of hospitals and hospital networks to purchase the patient monitoring, diagnostic cardiology and anesthesia systems that we sell or if it
will alter market-based incentives that hospitals and hospital networks currently face to continually improve, upgrade and expand their use of such equipment.
Efforts
by governmental and third-party payers to reduce healthcare costs or the implementation of new legislative reforms imposing additional government controls could cause a reduction
in sales or in the selling price of our products, which could adversely affect our business.
Substantial government regulation in the United States and abroad may restrict our ability to sell our patient monitoring, diagnostic cardiology and anesthesia systems, and
failure to comply with such laws and regulations may have a material adverse impact on our business.
The FDA and comparable regulatory authorities in foreign countries extensively and rigorously regulate our patient monitoring,
diagnostic cardiology and anesthesia systems, including the research and development, design, testing, clinical trials, manufacturing, clearance or approval, safety and efficacy, labeling,
advertising, promotion, pricing, recordkeeping, reporting, import and export, post-approval studies and sale and distribution of these products. In the United States, before we can market a new
medical device, or a new use of, new claim for, or significant modification to, an existing product, we must first receive either clearance under Section 510(k) of the Federal Food, Drug and
Cosmetic Act or approval of a premarket approval (PMA) application from the FDA, unless an exemption applies. In the 510(k) clearance process, the FDA must determine that a proposed device is
"substantially equivalent" to a device legally on the market, known as a "predicate" device, in order to clear the proposed device for marketing. To be "substantially equivalent," the proposed device
must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise
different questions of safety or effectiveness than the predicate device. Clinical data is sometimes required to support substantial equivalence. In the PMA approval process, the FDA must determine
that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, pre-clinical, clinical trial, manufacturing and labeling
data. The PMA process is typically required for devices for which the 510(k) process cannot be used and that are deemed to pose the greatest risk.
Modifications
to products that are approved through a PMA application generally need FDA approval, and some modifications made to products cleared through a 510(k) may require a new
510(k). The FDA can delay, limit or deny clearance or approval of a device for many reasons, including:
-
-
we may not be able to demonstrate to the FDA's satisfaction that our products are safe and effective for their intended uses;
-
-
the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required;
-
-
the manufacturing process or facilities we use may not meet applicable requirements; and
38
Table of Contents
-
-
the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a
manner rendering our clinical data or regulatory filings insufficient for clearance or approval.
Our
future products may not obtain FDA clearance on a timely basis, or at all. Further, the FDA makes periodic inspections of medical device manufacturers and in connection with such
inspections issues observations when the FDA believes the manufacturer has failed to comply with applicable regulations. If FDA observations are not addressed to the FDA's satisfaction, the FDA may
issue a warning letter and/or proceed directly to other forms of enforcement action, which could include the shutdown of our production facilities, adverse publicity, and civil and criminal penalties.
The expense and costs of any corrective actions that we may take, which may include product recalls, correction and removal of products from customer sites and/or changes to our product manufacturing
and quality systems, could adversely impact our financial results. Issuance of a warning letter may also lead customers to delay purchasing decisions or cancel orders.
In
August 2014, the FDA issued a warning letter to our Healthcare division, relating primarily to the maintenance of certain procedures and internal processes at our facility in
Snoqualmie, Washington. We have implemented corrective actions as a result of the warning letter and provided the FDA with a detailed response regarding our completed and in process activities.
However, there can be no assurance that the FDA will be satisfied with our response to the warning letter or our proposed resolution of the outstanding issues. Until the items raised in the warning
letter are fully corrected, we may be subject to additional regulatory action by the FDA, including the issuance of additional warning letters, injunction, seizure or recall of products, imposition of
fines or penalties or operating restrictions on our facilities. Such actions could significantly disrupt our ongoing business and operations and have a material adverse impact on our financial
position and operating results.
Our
patient monitoring, diagnostic cardiology, anesthesia systems and defibrillator products must also comply with the laws and regulations of foreign countries in which we develop,
manufacture and market such products. In general, the extent and complexity of medical device regulation is increasing worldwide. This trend is likely to continue and the cost and time required to
obtain marketing clearance in any given country may increase as a result. Our products may not obtain any necessary foreign clearances on a timely basis, or at all.
Once
any of our patient monitoring, diagnostic cardiology, anesthesia systems or defibrillator products is cleared for sale, regulatory authorities may still limit the use of such
product, prevent its sale or manufacture or require a recall or withdrawal of such product from the marketplace. Following initial clearance from regulatory authorities, we continue to be subject to
extensive regulatory requirements. Government authorities can withdraw marketing clearance or impose sanctions due to our failure to comply with regulatory standards or due to the occurrence of
unforeseen problems following initial clearance. Ongoing regulatory requirements are wide-ranging and govern, among other things:
-
-
annual inspections to retain a CE mark for sale of products in the European Union;
-
-
product manufacturing;
-
-
patient health data protection and medical device security;
-
-
supplier substitution;
-
-
product changes;
-
-
process modifications;
-
-
medical device reporting; and
-
-
product sales and distribution.
39
Table of Contents
Changes in laws affecting the healthcare industry could adversely affect our revenues and profitability.
We operate in a highly regulated industry. As a result, our business could be adversely affected by governmental actions, including
implementation of new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions; changes in the FDA and foreign regulatory approval processes that may
delay or prevent the approval of new products; and/or changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or
use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products, or otherwise
adversely affect the market for our products. We anticipate that governmental authorities will continue to scrutinize the healthcare industry closely and that additional regulation by governmental
authorities may cause increased compliance costs, exposure to litigation and other adverse effects to our operations.
We must continually monitor the performance of our products once approved and marketed for signs that their use may elicit serious and unexpected adverse effects. Any recall
of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our products that leads to corrective actions,
could have a material adverse impact on us.
Although we believe that existing data continue to support the efficacy and safety of our patient monitoring, cardiology, anesthesia
systems and defibrillator products, in the future, longer term study outcomes could demonstrate conflicting clinical effectiveness, a reduction of effectiveness,
no clinical effectiveness or longer term safety issues. This type of differing data could have a detrimental effect on the market penetration and usage of our medical device products. As a result, our
sales may decline or expected growth would be negatively impacted. This could negatively impact our operating condition and financial results.
More
generally, all medical devices can experience performance problems that require review and possible corrective action by us or a component supplier. We cannot provide assurance that
component failures, manufacturing errors, noncompliance with quality system requirements or good manufacturing practices, design defects and/or labeling inadequacies in any device that could result in
an unsafe condition or injury to the patient will not occur. The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of
material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. Manufacturers may also, under their own initiative, stop
shipment or recall a product if any material deficiency is found or withdraw a product to improve device performance or for other reasons. A government-mandated or voluntary recall by us or one of our
distributors could occur as a result of an unacceptable risk to health, component failures, manufacturing errors, noncompliance with good manufacturing practices or quality system requirements, design
or labeling defects or other deficiencies and issues. Similar regulatory agencies in other countries have similar authority to recall products because of material deficiencies or defects in design or
manufacture that could endanger health. A recall involving our products could be particularly harmful to our business, financial and operating results.
The
FDA requires that certain classifications of recalls be reported to the FDA within 10 working days after the recall is initiated. Notice to the FDA of a correction or removal is
required when undertaken to reduce a risk to health, including when there is a reasonable probability that the product will cause serious adverse health consequences or death, or when use of the
device may cause temporary or medically reversible adverse health consequences or an outcome where the probability of serious adverse health consequences is remote. In addition, companies are required
to maintain certain records of corrections and removal, even if they are not reportable to the FDA or similar foreign governmental authorities. We may initiate voluntary recalls involving our products
in the future that we determine do not require notification of the FDA or foreign governmental authorities. If the FDA or foreign governmental authorities disagree with our determinations, they could
require us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively affect our sales. In addition, the FDA or a foreign governmental
authority could take enforcement action for failing to report the recalls when they were conducted.
40
Table of Contents
In
addition, under the FDA's medical device reporting regulations, we are required to report to the FDA any incident in which our product may have caused or contributed to a death or
serious injury or in which our product malfunctioned and, if the malfunction were to recur, would likely cause or contribute to death or serious injury. Repeated product malfunctions may result in a
voluntary or involuntary product recall.
Depending
on the corrective action we take to redress a product's deficiencies or defects, the FDA or applicable foreign regulatory authority may require, or we may decide, that we will
need to obtain new approvals or clearances for the device before we may market or distribute the corrected device. Seeking such approvals or clearances may delay our ability to replace the recalled
devices in a timely manner. Moreover, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties, civil penalties or
criminal fines. We may also be required to bear other costs or take other actions that may have a negative impact on our sales as well as face material adverse publicity or regulatory consequences,
which could harm our business, including our ability to market our products in the future.
Any
adverse event involving our products, whether in the United States or abroad, could result in future voluntary corrective actions, such as recalls or customer notifications, or
agency action, such as inspection, mandatory recall, orders of repair, replacement or refund or other enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending
ourselves in a lawsuit, will require the dedication of our time and capital and may harm our reputation and financial results.
We may be subject to fines, penalties, injunctions or other enforcement actions if we are determined to be promoting the use of our products for unapproved or "off-label"
uses, resulting in damage to our reputation and business.
Our promotional materials and training methods must comply with FDA and other applicable laws and regulations, including the
prohibition of the promotion of a medical device for a use that has not been cleared or approved by the FDA. Use of a device outside of its cleared or approved indications is known as "off-label" use.
Physicians may use our products off-label, as the FDA does not restrict or regulate a physician's choice of treatment within the practice of medicine. However, if the FDA determines that our
promotional materials or training constitutes promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions,
including the issuance of warning letters, untitled letters, fines, penalties, consent decrees, injunctions, or seizures, which could have an adverse impact on our reputation and financial results. We
could also be subject to enforcement action under other federal or state laws, including the False Claims Act.
We are subject to additional federal, state and foreign laws and regulations relating to our healthcare business; our failure to comply with those laws could have a material
adverse effect on our results of operations and financial condition.
Although we do not provide healthcare services, submit claims for third-party reimbursement or receive payments directly from Medicare,
Medicaid or other third-party payers for our product, we are subject to healthcare fraud and abuse regulation and enforcement by federal and state governments, which could significantly impact our
business. Healthcare fraud and abuse and health information privacy and security laws potentially applicable to our operations include:
-
-
the federal Anti-Kickback Statute, which applies to our marketing practices, pricing policies and relationships with healthcare
providers, by prohibiting, among other things, soliciting, receiving, offering or providing remuneration intended to induce the purchase or recommendation of an item or service reimbursable under a
federal healthcare program, such as the Medicare or Medicaid programs;
-
-
federal civil and criminal false claims laws and civil monetary penalty laws, including civil whistleblower or qui tam actions, that
prohibit, among other things, knowingly presenting, or causing to be presented, claims
41
Table of Contents
for
payment or approval to the federal government that are false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or property to the federal
government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay or transmit money or property to the federal government;
-
-
the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) and its implementing regulations, which created
federal criminal laws that prohibit, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;
-
-
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH), imposes certain regulatory and
contractual requirements regarding the privacy, security and transmission of individually identifiable health information;
-
-
federal "Sunshine Act" requirements imposed by the Affordable Care Act, on device manufacturers regarding any "payment or other
transfer of value" to physicians and teaching hospitals. Failure to submit required information may result in civil monetary penalties of up to an aggregate of $150,000 per year (or up to an aggregate
of $1 million per year for "knowing failures") for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual
submission; and
-
-
state and foreign law equivalents of each of the above federal laws, such as state anti-kickback and false claims laws that may apply
to items or services reimbursed by any third-party payer, including commercial insurers; state laws that require device companies to comply with the industry's voluntary compliance guidelines and the
relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state laws that require drug and device manufacturers to
report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state laws governing the privacy and security of certain
health information, many of which differ from each other in significant ways and often are not preempted by HIPAA/HITECH, thus complicating compliance efforts.
The
risk of our being found in violation of these laws and regulations is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the
courts, and their provisions are open to a variety of interpretations. Moreover, recent health care reform legislation has strengthened these laws. For example, the Affordable Care Act, among other
things, amended the intent requirement of the federal Anti-Kickback Statute and criminal health care fraud statutes; a person or entity no longer needs to have actual knowledge of these statutes or
specific intent to violate them to have committed a violation. In addition, the Affordable Care Act provided that the government may assert that a claim including items or services resulting from a
violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.
Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under such laws, it is possible that some of our business activities could
be subject to challenge under one or more of such laws. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses
and divert our management's attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that
apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from governmental health care programs, disgorgement, contractual damages, reputational
harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could impair our ability to operate our business and our financial results.
42
Table of Contents
Consolidation in the healthcare industry could have an adverse effect on our revenues and results of operations.
The healthcare industry has been consolidating and organizations such as group purchasing organizations, independent delivery networks,
and large single accounts such as the United States Veterans Administration, continue to consolidate purchasing decisions for many of our healthcare provider customers. As a result, transactions with
customers are larger, more complex, and tend to involve more long-term contracts. The purchasing power of these larger customers has increased, and may continue to increase, causing downward pressure
on product pricing. If we are not one of the providers selected by one of these organizations, we may be precluded from making sales to its members or participants. Even if we are one of the selected
providers, we may be at a disadvantage relative to other selected providers that are able to offer volume discounts based on purchases of a broader range of products. Further, we may be required to
commit to pricing that has a material adverse effect on our revenues and profit margins, business, financial condition and results of operations. We expect that market demand, governmental regulation,
third-party reimbursement policies and societal pressures will continue to change the worldwide healthcare industry, resulting in further business consolidations and alliances, which may exert further
downward pressure on the prices of our products and could adversely impact our business, financial condition, and results of operations.
Technological advances and evolving industry and regulatory standards and certifications could reduce our future product sales, which could cause our revenues to grow more
slowly or decline.
The markets for our products are characterized by rapidly changing technology, changing customer needs, evolving industry or regulatory
standards and certifications and frequent new product introductions and enhancements. The emergence of new industry or regulatory standards and certification requirements in related fields may
adversely affect the demand for our products. This could happen, for example, if new standards and technologies emerged that were incompatible with customer deployments of our applications. In
addition, any products or processes that we develop may become obsolete or uneconomical before we recover any of the expenses incurred in connection with their development. We cannot provide assurance
that we will succeed in developing and marketing product enhancements or new products that respond to technological change, new industry standards, changed customer requirements or competitive
products on a timely and cost-effective basis. Additionally, even if we are able to develop new products and product enhancements, we cannot provide assurance that they will be profitable or that they
will achieve market acceptance.
We
develop certain of our security inspection technologies to meet the certification requirements of various agencies worldwide, including the U.S. Transportation Safety Administration
and the European Civil Aviation Conference among others. Such standards frequently change and there is a risk now and in the future that we may not ultimately be able to develop technologies, or
develop in a timely way, solutions that are ultimately able to meet the new standards.
We are subject to various environmental regulations which may impose liability on us whether or not we knew of or caused the release of hazardous substances on or in our
facilities.
We are subject to various U.S. and international environmental laws, directives, and regulations pertaining to the use, storage,
handling and disposal of hazardous substances used, and hazardous wastes used or generated, in the manufacture of our products. Such laws mandate the use of controls and practices designed to mitigate
the impact of our operations on the environment, and under such laws we may be held liable for the costs associated with the remediation and removal of any unintended or previously unknown releases of
hazardous substances on, beneath or from our property and associated operations, including the remediation of hazardous waste disposed off-site. Such laws may impose liability without regard to
whether we knew of or caused the release of such hazardous substances or wastes. For example, we continue to investigate soil and groundwater contamination at our Hawthorne, California facility that
we believe stems from historical releases and off-site sources. See "BusinessEnvironmental Regulations". Any failure by us to comply with present or future regulations could subject us to
the imposition of substantial fines, suspension of production, alteration of manufacturing processes, or cessation of operations, any of which could have a material adverse effect on our business,
financial condition and results of operations.
43
Table of Contents
A failure of a key information technology system, process or site could have a material adverse impact on our ability to conduct business.
We rely extensively on information technology systems to interact with our employees and our customers. These interactions include, but
are not limited to, ordering and managing materials from suppliers, converting materials to finished products, shipping product to customers, processing transactions, summarizing and reporting results
of operations, transmitting data used by our service personnel and by and among our wide-spread operations, complying with regulatory, legal and tax requirements, and other processes necessary to
manage our business. If our systems are damaged or cease to function properly due to any number of causes, ranging from the failures of third-party service providers, to catastrophic events, to power
outages, to security breaches, and our business continuity plans do not effectively compensate on a
timely basis, we may suffer interruptions in our ability to manage operations which may adversely impact our results of operations and/or financial condition.
Increased cybersecurity requirements, vulnerabilities, threats and more sophisticated and targeted computer crime could pose a risk to our systems, networks, products,
services and data.
Increased global cybersecurity vulnerabilities, threats and more sophisticated and targeted cyber-related attacks pose a risk to the
security of our Company's and our customers', suppliers' and third-party service providers' products, systems and networks and the confidentiality, availability and integrity of our and our customers'
data. Although we have implemented policies, procedures and controls to protect against, detect and mitigate these threats, we remain potentially vulnerable to additional known or unknown threats. We
also have access to sensitive, confidential or personal data or information that is subject to privacy and security laws, regulations and customer-imposed controls. Despite our efforts to protect
sensitive, confidential or personal data or information, we may be vulnerable to material security breaches, theft, misplaced or lost data, programming errors, employee errors and/or malfeasance that
could potentially lead to the compromising of sensitive, confidential or personal data or information, improper use of our systems or networks, unauthorized access, use, disclosure, modification or
destruction of information, defective products, production downtimes and operational disruptions. In addition, a cyber-related attack could result in other negative consequences, including damage to
our reputation or competitiveness and remediation or increased protection costs, and could subject us to fines, damages, litigation and enforcement actions.
We may experience difficulties implementing our new global enterprise resource planning system.
We are engaged in a multi-year implementation of a new global enterprise resource planning system (ERP). The ERP is designed to
accurately maintain our books and records and provide information important to the operation of our business to our management team. Our ERP will continue to require significant investment of human
and financial resources. In implementing the ERP, we may experience significant delays, increased costs and other difficulties. Any significant disruption or deficiency in the design and
implementation of the ERP could adversely affect our ability to process orders, ship product, send invoices and track payments, fulfill contractual obligations or otherwise operate our business. While
we have invested significant resources in planning and project management, significant implementation issues may arise.
We receive significant amounts of research and development funding for our security and inspection systems from government grants and contracts, but we may not receive
comparable levels of funding in the future.
The U.S. Government currently plays an important role in funding the development of certain of our security and inspection systems and
sponsoring their deployment at airports, ports, military installations and border crossings. However, in the future, additional research and development funds from the government may not be available
to us. If the government does not sponsor our technologies in the future, we may have to expend more resources on product development or cease development of certain technologies, which could
adversely affect our business. Government funded research and development also presents risks associated with government contracting
44
Table of Contents
in
general that are described elsewhere in our risk factors. Government agencies can generally terminate their contracts for convenience, and if we fail to meet the goals of government funded research
and development, there is a risk that the government agency may terminate our contracts for default. In addition, any future grants to our competitors may improve their ability to develop and market
competing products and cause our customers to delay purchase decisions, which could harm our ability to market our products.
Certain of our U.S. Government contracts are dependent upon our employees obtaining and maintaining required security clearances, as well as our ability to obtain security
clearances for the facilities in which we perform sensitive government work.
Certain of our U.S. Government contracts require our employees to maintain various levels of security clearances, and we are required
to maintain certain facility security clearances. If we cannot maintain or obtain the required security clearances for our facilities and our employees, or obtain these clearances in a timely manner,
we may be unable to perform certain U.S. Government contracts. Further, loss of a facility clearance, or an employee's failure to obtain or maintain a security clearance, could result in a U.S.
Government customer terminating an existing contract or choosing not to renew a contract. Lack of required clearances could also impede our ability to bid on or win new U.S. Government contracts. This
could damage our reputation and adversely affect our business, financial condition and results of operations.
We are involved in various litigation matters, which could have a material adverse effect on our business, financial condition or operating results.
Litigation can be lengthy, expensive and disruptive to our operations, and can divert our management's attention away from the running
of our business. Claims arising out of actual or alleged violations of law could be asserted against us by individuals, either individually or through class actions, or by governmental entities in
investigations and proceedings. If the Company is unsuccessful in its defense in litigation matters, or any other legal proceeding, it may be forced to pay damages or fines and/or change its business
practices, any of which could have a material adverse effect on the Company's business, financial condition and results of operations. For more information about the Company's litigation matters, see
"Legal Proceedings" and note 9 to the consolidated financial statements.
Our credit facility contains provisions that could restrict our ability to finance our future operations or engage in other business activities that may be in our interest.
Our credit facility contains a number of significant covenants that, among other things, limit our ability
to:
-
-
dispose of assets;
-
-
incur certain additional indebtedness;
-
-
repay certain indebtedness;
-
-
create liens on assets;
-
-
pay dividends on our Common Stock;
-
-
make certain investments, loans and advances;
-
-
repurchase or redeem capital stock;
-
-
make certain capital expenditures;
-
-
engage in acquisitions, mergers or consolidations; and
-
-
engage in certain transactions with subsidiaries and affiliates.
45
Table of Contents
These
covenants could limit our ability to plan for or react to market conditions, finance our operations, engage in strategic acquisitions or disposals or meet our capital needs or
could otherwise restrict our activities or business plans. Our ability to comply with these covenants may be affected by events beyond our control. In addition, our credit facility also requires us to
maintain compliance with certain financial ratios. Our inability to comply with the required financial ratios or covenants could result in an event of default under our credit facility. A default, if
not cured or waived, may permit acceleration of our indebtedness. In addition, our lenders could terminate their commitments to make further extensions of credit under our credit facility. If our
indebtedness is accelerated, we cannot be certain that we will have sufficient funds to pay the
accelerated indebtedness or that we will have the ability to refinance accelerated indebtedness on terms favorable to us or at all.
Changes in our tax rates could affect our future financial results.
Our future effective tax rates could be favorably or unfavorably affected by changes in the valuation of our deferred tax assets and
liabilities, or by changes in tax laws or their interpretation. In addition, we are subject to the examination of our income tax returns by the Internal Revenue Service and other tax authorities. We
regularly assess the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of our provision for income taxes. There can be no assurance that the outcomes from
these examinations will not have an adverse effect on our operating results and financial condition.
Changes in tax laws or tax rulings could materially affect our financial position and results of operations.
Changes in tax laws or tax rulings could materially affect our financial position and results of operations. For example, the current
U.S. administration and key members of Congress have made public statements indicating that tax reform is a priority. Certain changes to U.S. tax laws, including limitations on the ability to defer
U.S. taxation on earnings outside of the United States until those earnings are repatriated to the United States, could affect the tax treatment of our foreign earnings. In addition, many countries in
the European Union, as well as a number of other countries and organizations such as the Organization for Economic Cooperation and Development, are actively considering changes to existing tax laws.
Certain proposals could include recommendations that would significantly increase our tax obligations in many countries where we do business. Due to the large and expanding scale of our international
business activities, any changes in the taxation of such activities may increase our worldwide effective tax rate and harm our financial position and results of operations.
If goodwill or other intangible assets in connection with our acquisitions become impaired, we could take significant non-cash charges against earnings.
We have pursued and will continue to seek potential acquisitions to complement and expand our existing businesses, increase our
revenues and profitability, and expand our markets. As a result of prior acquisitions, we have goodwill and intangible assets recorded on our balance sheet as described in note 4 to our
consolidated financial statements. Under current accounting guidelines, we must assess, at least annually, whether the value of goodwill and other intangible assets has been impaired. Any reduction or
impairment of the value of goodwill or other intangible assets will result in charges against earnings, which could adversely affect our results of operations in future periods.
Our Certificate of Incorporation and other agreements contain provisions that could discourage a takeover.
Our Certificate of Incorporation authorizes our Board of Directors to issue up to 10,000,000 shares of Preferred Stock in one or more
series, to fix the rights, preferences, privileges and restrictions of Preferred Stock, to fix the number of shares constituting any such series and to fix the designation of any such series, without
further vote or action by stockholders. The terms of any series of Preferred Stock, which may include economic rights
46
Table of Contents
senior
to our Common Stock and special voting rights, could adversely affect the rights of the holders of our Common Stock and thereby reduce the value of our Common Stock. The issuance of Preferred
Stock, coupled with the concentration of ownership in the directors and executive officers, could discourage certain types of transactions involving an actual or potential change in control of our
company, including transactions in which the holders of Common Stock might otherwise receive a premium for their shares over then current prices, could otherwise dilute the rights of holders of Common
Stock and may limit the ability of such stockholders to cause or approve transactions which they may deem to be in their best interests, all of which could have a material adverse effect on the market
price of our Common Stock.
Our Certificate of Incorporation limits the liability of our directors, which may limit the remedies we or our stockholders have available.
Our Certificate of Incorporation provides that, pursuant to the Delaware General Corporation Law, the liability of our directors for
monetary damages shall be eliminated to the fullest extent permissible under Delaware law, as that law exists currently and as it may be amended in the future. This is intended to eliminate the
personal liability of a director for monetary damages in an action brought by us, or in our right for breach of a director's duties to us or our stockholders and may limit the remedies available to us
or our stockholders. Under Delaware law, this provision does not apply to eliminate or limit a director's monetary liabilities for: (i) breaches of the director's duty of loyalty to us or our
stockholders; (ii) acts or omissions not in good faith or which involve intentional misconduct or knowing violations of law; (iii) the unlawful payment of dividends or unlawful stock
repurchases or redemptions under Section 174 of the Delaware General Corporation Law or (iv) transactions in which the director received an improper personal benefit. Additionally, under
Delaware law, this provision does not limit a director's liability for the violation of, or otherwise relieve us or our directors from complying with, federal or state securities laws, nor does it
limit the availability of non-monetary remedies such as injunctive relief or rescission for a violation of federal or state securities laws.
New regulations related to conflict minerals may force us to incur additional expenses, may make our supply chain more complex and may result in damage to our relationships
with customers.
Under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC adopted requirements for companies that
manufacture products that contain certain minerals and metals, known as conflict minerals. These rules require public companies to perform diligence and to report annually to the SEC whether such
minerals originate from the Democratic Republic of Congo and adjoining countries. These requirements could adversely affect the sourcing, availability and pricing of minerals we use in the manufacture
of certain of our products. In addition, we incur additional costs to comply with the disclosure requirements, including costs related to determining the source of any of the relevant minerals used in
our products. Since our supply chain is complex, we may not be able to ascertain the origins for these minerals used in our products through the due diligence procedures that we implement, which may
harm our reputation. We may also face difficulties in satisfying customers who may require that our products be certified as conflict mineral free, which could harm our relationships with these
customers and lead to a loss of revenue. These requirements could limit the pool of suppliers that can provide conflict-free minerals, and we may be unable to obtain conflict-free minerals at
competitive prices, which could increase our costs and adversely affect our manufacturing operations and our profitability.
Risks Related to Our Pending Acquisition of American Science and Engineering, Inc.
There can be no assurance that the acquisition of AS&E will be completed.
On June 20, 2016, we signed a definitive agreement to acquire AS&E. We expect the acquisition to close by December 31,
2016. However, the transaction is subject to a number of conditions that must be fulfilled in order to complete the acquisition. Those conditions include continued accuracy of the representations and
warranties by both parties and the performance by both parties of their covenants and agreements, approval by AS&E's
47
Table of Contents
shareholders,
absence of any order or injunction prohibiting the completion of the acquisition and certain other customary conditions specified in the agreement. In addition, both we and AS&E have
rights to terminate the agreement under certain circumstances specified in the agreement.
Obtaining required regulatory approvals may prevent or delay consummation of the acquisition of AS&E, reduce the anticipated benefits of the acquisition or require changes
to the structure or terms of the acquisition.
Consummation of the acquisition of AS&E is conditioned upon, among other things, the expiration or termination of the waiting period
(and any extensions thereof) applicable to the acquisition under the HSR Act. At any time before or after the acquisition is consummated, any of the Department of Justice, the Federal Trade Commission
or U.S. state Attorneys General could take action under the antitrust laws in opposition to the acquisition, including seeking to enjoin completion of the acquisition, conditioning completion of the
acquisition upon the divestiture of assets of the Company, AS&E, our or its subsidiaries or imposing restrictions on our post-acquisition operations. These could negatively affect our results of
operations and financial condition following completion of the acquisition. Any such requirements or restrictions may prevent or delay consummation of the acquisition or may reduce the anticipated
benefits of the acquisition, which could also have a material adverse effect on our business, cash flows, financial condition and results of operations. No assurance can be given that the required
regulatory approvals will be obtained or that the required conditions to closing will be satisfied, and, even if all such approvals are obtained and the conditions are satisfied, no assurance can be
given as to the terms, conditions and timing of the approvals.
We have made certain assumptions relating to the acquisition of AS&E that may prove to be materially inaccurate.
We have made certain assumptions relating to the acquisition of AS&E, including, for
example:
-
-
projections of AS&E's future revenues;
-
-
the amount of goodwill and intangibles that will result from the acquisition;
-
-
certain other purchase accounting adjustments that we expect will be recorded in our financial statements in connection with the
acquisition;
-
-
acquisition costs, including transaction and integration costs;
-
-
the amount of AS&E's cash and cash equivalents as of the merger date;
-
-
the amount of cost savings as a result of synergies from the merger;
-
-
our ability to maintain, develop and deepen relationships with AS&E's customers;
-
-
potential outcomes of, and contingencies related to, the ongoing investigation of AS&E by the U.S. General Services Administration, or
GSA, regarding its GSA contracting activity; and
-
-
other financial and strategic rationales and risks of the acquisition.
While
management has made such assumptions in good faith and believes them to be reasonable, the assumptions may turn out to be materially inaccurate, including for reasons beyond our control. If
these assumptions are incorrect we may change or modify our assumptions, such change or modification could have a material adverse effect on our financial condition or results of operations.
48
Table of Contents
Any failure to successfully integrate AS&E's business and operations or fully realize potential synergies from the acquisition of AS&E in the expected timeframe or at all
would adversely affect our business, operating results and financial condition.
We do not have a history of acquiring businesses of the size and complexity of AS&E, and the success of the acquisition will depend, in
part, on our ability to successfully integrate AS&E's business and operations and fully realize the anticipated benefits and potential synergies from combining our business with AS&E's business. To
realize these anticipated benefits and potential synergies, we must successfully combine these businesses. If we are unable to achieve these objectives following the acquisition, the anticipated
benefits and potential synergies of the acquisition may not be realized fully or at all, or may take longer to realize than expected. Any failure to timely realize these anticipated benefits would
have a material adverse effect on our business, operating results and financial condition. We and AS&E have operated and, until the completion of the acquisition, will continue to operate
independently. The integration process could result in the loss of key employees, loss of key customers, decreases in revenue and increases in operating costs, as well as the disruption of each
company's ongoing businesses, any or all of which could limit our ability to achieve the anticipated benefits and synergies of the acquisition and have a material adverse effect on our business,
operating results and financial condition.
We and AS&E may have difficulty attracting, motivating and retaining executives and other key employees in light of the acquisition.
Uncertainty about the effect of the acquisition on our and AS&E's employees may have an adverse effect on us or AS&E and, consequently,
the combined business resulting from the acquisition. This uncertainty may impair our and AS&E's ability to attract, retain and motivate key personnel until the acquisition is completed, or longer for
the combined entity. Employee retention may be particularly challenging during the pendency of the acquisition as our and AS&E's employees may experience uncertainty about their future roles with the
combined business. Additionally, AS&E's officers and employees own shares of AS&E's common stock and/or hold options to purchase AS&E's common stock or restricted stock awards granted by AS&E. If the
acquisition is completed, they will be entitled to receive a portion of the consideration for the acquisition, the payment of which could provide sufficient financial incentive for certain officers
and employees to no longer pursue employment with the combined business. If key employees depart
because of issues relating to the uncertainty and difficulty of integration, financial incentives or a desire not to become employees of the combined business, we may incur significant costs in
identifying, hiring and retaining replacements for departing employees, which could substantially reduce or delay our ability to realize the anticipated benefits of the acquisition.
Our and AS&E's business relationships, including customer relationships, may be subject to disruption due to uncertainty associated with the acquisition.
Parties with which we or AS&E do business may experience uncertainty associated with the acquisition, including with respect to current
or future business relationships with us, AS&E or the combined business. These business relationships may be subject to disruption as customers and others may attempt to negotiate changes in existing
business relationships or consider entering into business relationships with parties other than us, AS&E or the combined business, including our competitors or those of AS&E. These disruptions could
have a material adverse effect on the businesses, operating results and financial condition of the combined business. The adverse effect of such disruptions could be exacerbated by a delay in the
completion of the acquisition or termination of the merger agreement.
We have incurred, and will continue to incur, significant transaction expenses and acquisition-related integration costs in connection with the AS&E acquisition.
We have incurred, and will continue to incur, significant transaction costs relating to the negotiation and completion of the
acquisition. Except in limited circumstances, we will have to bear these costs whether or not the acquisition is completed. Additionally, we are currently developing a plan to integrate the operations
of AS&E with
49
Table of Contents
our
own after the completion of the acquisition. In connection with that plan, we anticipate that we will incur certain non-recurring charges in connection with this integration; however, we cannot
yet identify the timing, nature and amount of all such charges. These transaction expenses and integration costs will be charged as an expense in the period incurred; although many of these
transaction costs may not be deductible for income tax purposes, thus, raising our effective tax rate. The significant transaction costs and acquisition-related integration costs could materially
affect our results of operations in the period in which such charges are recorded. Although we believe that the elimination of duplicative costs, as well as the realization of other efficiencies
related to the integration of the business, will offset incremental transaction and acquisition-related costs over time, this net benefit may not be achieved in the near-term, or at all.
Increased leverage, as a result of the pending AS&E acquisition, may harm our financial condition and results of operations.
As of June 30, 2016, we had approximately $134 million of total debt on a consolidated basis. We expect our indebtedness
to increase materially in connection with the pending acquisition of AS&E, as we expect to borrow under our revolving credit facility to fund the acquisition. This increase and any future increase in
our level of indebtedness will have several important effects on our future operations, including, without limitation:
-
-
we will have additional cash requirements in order to support the payment of interest on our outstanding indebtedness;
-
-
increases in our outstanding indebtedness and leverage may increase our vulnerability to adverse changes in our business;
-
-
our ability to obtain additional financing for working capital, capital expenditures, general corporate and other purposes may be
reduced;
-
-
our flexibility in planning for, or reacting to, changes in our business and our industry may be reduced; and
-
-
our flexibility to make acquisitions and develop new products may be limited.
We may write-off intangible assets, such as goodwill in connection with the AS&E acquisition.
We expect to record intangible assets, including goodwill in connection with the acquisition of AS&E. Pursuant to our accounting
policy, on a periodic basis, we will evaluate whether facts and circumstances indicate any impairment of the value of intangible assets. As circumstances change, we cannot assure you that the value of
these intangible assets will be realized by us. If we determine that a significant impairment has occurred, we will be required to write-off the impaired portion of intangible assets, which could have
a material adverse effect on our results of operations in the period in which the write-off occurs.
ITEM 1B. UNRESOLVED STAFF COMMENTS
None.
50
Table of Contents
ITEM 2. PROPERTIES
As of June 30, 2016, we owned the following principal facilities (
i.e.
,
facilities greater than 50,000 square feet):
|
|
|
|
|
|
|
Location
|
|
Description of Facility
|
|
Approximate
Square Footage
|
|
Hawthorne, California
|
|
Corporate headquarters and administrative, manufacturing, engineering, sales and marketing and service for our Optoelectronics and Manufacturing division
|
|
|
88,000
|
|
Snoqualmie, Washington (1)
|
|
Headquarters and administrative, manufacturing, engineering, sales, marketing and service for our Healthcare division
|
|
|
177,000
|
|
Stoke on Trent, United Kingdom
|
|
Manufacturing, engineering, sales, marketing and service for our Security division
|
|
|
90,000
|
|
Surrey, United Kingdom (1)
|
|
Manufacturing, engineering, sales and marketing and service for our Security division
|
|
|
59,000
|
|
Batam, Indonesia
|
|
Manufacturing for our Optoelectronics and Manufacturing division
|
|
|
59,000
|
|
-
(1)
-
Each
of these facilities is encumbered by a mortgage.
51
Table of Contents
As
of June 30, 2016, we leased the following principal facilities (
i.e.
, facilities greater than 50,000 square feet):
|
|
|
|
|
|
|
|
Location
|
|
Description of Facility
|
|
Approximate
Square Footage
|
|
Expiration
|
Batam, Indonesia (1)
|
|
Manufacturing for our Optoelectronics and Manufacturing division
|
|
|
94,700
|
|
2017 ~ 2019
|
Torrance, California
|
|
Manufacturing, engineering, sales and marketing and service for our Security division
|
|
|
91,900
|
|
2017
|
Johor Bahru, Malaysia
|
|
Manufacturing, engineering, sales and service for our Security division
|
|
|
89,000
|
|
2018
|
Johor Bahru, Malaysia
|
|
Manufacturing, engineering, sales and service for our Optoelectronics and Manufacturing division
|
|
|
71,000
|
|
2017
|
Garner, North Carolina
|
|
Manufacturing, engineering, sales and marketing and service for our Security division
|
|
|
68,000
|
|
2017
|
Sunnyvale, California
|
|
Manufacturing, engineering, sales and marketing and service for our Security division
|
|
|
62,500
|
|
2017
|
Suzhou, China
|
|
Manufacturing, engineering, sales and marketing and service for our Healthcare division
|
|
|
53,000
|
|
2017
|
Hyderabad, India (2)
|
|
Manufacturing and engineering for our Security, Healthcare and Optoelectronics and Manufacturing divisions
|
|
|
50,400
|
|
2021
|
-
(1)
-
This
is comprised of five leases, ranging in size between 11,000 square feet and 37,400 square feet, at the same or nearby facilities.
-
(2)
-
This
is comprised of three leases, ranging in size between 5,000 square feet and 33,600 square feet, at the same or nearby facilities.
We
believe that our facilities are in good condition to support our current operations but will expand as necessary to support our growth. We currently anticipate that we will be able to
renew the leases that are scheduled to expire in the next few years on terms that are substantially the same as those currently in effect. However, even if we were not able to renew one or more of the
leases, we believe that suitable substitute space is available to relocate any of the facilities. Accordingly, we do not believe that our failure to renew any of the leases that are scheduled to
expire in the next few years will have a material adverse effect on our operations.
ITEM 3. LEGAL PROCEEDINGS
Three shareholder derivative complaints (the "Derivative Actions") have been filed purportedly on behalf of the Company against the
members of the Company's Board of Directors (as individual defendants).
Hagan v. Chopra et al.
was filed in the United States District Court for the
Central District of California (the "Court") on April 15, 2014, and was subsequently consolidated by the Court with
City of Irving Benefit Plan v. Chopra et
al.
, which was filed on December 29, 2014.
Kocen v. Chopra et al.
was filed in the Delaware Court of Chancery on
July 14, 2015. The Derivative Actions generally assert claims for breach of fiduciary duties and unjust enrichment
52
Table of Contents
against
the individual defendants on behalf of the Company. Plaintiffs in the Derivative Actions seek unspecified damages, restitution, injunctive relief, attorneys' and experts' fees, costs,
expenses, and other unspecified relief. Following a mediation and post-mediation settlement discussions, the parties to the Derivative Actions reached a settlement and have signed a settlement term
sheet, which, if approved, would provide for the resolution of all pending claims in both the California and Delaware actions. The Company and the other defendants agreed to the settlement term sheet
to avoid further expense, inconvenience, and the distraction and inherent risks of burdensome and protracted litigation. Neither the Company nor the individual defendants conceded any wrongdoing or
liability, and each continue to believe that they have meritorious defenses to all claims alleged in the Derivative Actions. The settlement is subject to approval by the Court and certain other
conditions.
We
are involved in various other claims and legal proceedings arising in the ordinary course of business. In our opinion after consultation with legal counsel, the ultimate disposition
of such proceedings is not likely to have a material adverse effect on our business, financial condition, results of operations or cash flows. We have not accrued for loss contingencies relating to
such matters because we believe that, although unfavorable outcomes in the proceedings may be possible, they are not considered by management to be probable or reasonably estimable. If one or more of
these matters are resolved in a manner adverse to the Company, the impact on our business, financial condition, results of operations and liquidity could be material.
ITEM 4. MINE SAFETY DISCLOSURES
None.
53
Table of Contents
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Stock Market and Other Information
Our Common Stock is traded on The NASDAQ Global Select Market under the symbol "OSIS."
The
following table sets forth the high and low sale prices of a share of our Common Stock as reported by The NASDAQ Global Select Market on a quarterly basis for fiscal 2015 and 2016.
The prices shown reflect inter-dealer prices, without retail markup, markdown or commission and may not necessarily represent actual transactions.
|
|
|
|
|
|
|
|
2015:
|
|
High
|
|
Low
|
|
Quarter ended September 30, 2014
|
|
$
|
70.27
|
|
$
|
62.10
|
|
Quarter ended December 31, 2014
|
|
$
|
74.79
|
|
$
|
58.54
|
|
Quarter ended March 31, 2015
|
|
$
|
75.00
|
|
$
|
66.90
|
|
Quarter ended June 30, 2015
|
|
$
|
76.70
|
|
$
|
66.03
|
|
|
|
|
|
|
|
|
|
2016:
|
|
High
|
|
Low
|
|
Quarter ended September 30, 2015
|
|
$
|
79.28
|
|
$
|
66.94
|
|
Quarter ended December 31, 2015
|
|
$
|
96.75
|
|
$
|
75.60
|
|
Quarter ended March 31, 2016
|
|
$
|
88.33
|
|
$
|
48.19
|
|
Quarter ended June 30, 2016
|
|
$
|
66.43
|
|
$
|
48.76
|
|
As
of August 15, 2016, there were approximately 124 holders of record of our Common Stock. This number does not include beneficial owners holding shares through nominees or in
"street" name.
Dividend Policy
We have not paid any cash dividends since the consummation of our initial public offering in 1997 and we do not currently intend to pay
any cash dividends in the foreseeable future. Our Board of Directors will determine the payment of future cash dividends, if any. Certain of our current bank credit facilities restrict the payment of
cash dividends and future borrowings may contain similar restrictions.
Issuer Purchases of Equity Securities
The following table presents the shares acquired during the quarter ended June 30, 2016:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total number of
shares (or units)
Purchased (1)
|
|
Average price
paid per share
(or unit)
|
|
Total number of
shares (or units)
purchased as
part of publicly
announced plans or
programs
|
|
Maximum number
(or approximate
dollar value)
of shares (or units)
that may
yet be purchased
under the plans or
programs (2)
|
|
April 1, 2016 to April 30, 2016
|
|
|
1,431
|
|
$
|
60.17
|
|
|
0
|
|
|
1,063,158
|
|
May 1, 2016 to May 31, 2016
|
|
|
186
|
|
$
|
50.89
|
|
|
0
|
|
|
1,063,158
|
|
June 1, 2016 to June 30, 2016
|
|
|
7,727
|
|
$
|
55.95
|
|
|
0
|
|
|
1,063,158
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,344
|
|
$
|
56.50
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
(1)
-
Represent
shares of Common Stock tendered to satisfy minimum statutory tax withholding obligations related to the vesting of restricted shares.
54
Table of Contents
-
(2)
-
In
March 1999, the Board of Directors authorized a stock repurchase program of up to two million shares. In each of September 2004 and April 2013, the Board
of Directors authorized an additional one million shares for repurchase pursuant to this program, and in October 2015 the Board of Directors authorized an additional 500,000 shares for repurchase
pursuant to this program. In April 2016, the Board of Directors authorized a new stock repurchase program of up to one million shares. The shares of Common Stock authorized to be repurchased under the
new repurchase program are in addition to the 63,158 shares remaining under the Company's existing stock repurchase program. These programs do not have expiration dates. Upon repurchase, the shares
are restored to the status of authorized but unissued, and we record them as a reduction in the number of shares of Common Stock issued and outstanding in the consolidated financial statements.
Equity Compensation Plans
The following table provides information concerning our equity compensation plans as of June 30, 2016.
|
|
|
|
|
|
|
|
|
|
|
Plan category
|
|
Number of securities to
be issued upon exercise
of outstanding options,
warrants and rights
|
|
Weighted-average
exercise price of
outstanding options,
warrants and rights
|
|
Number of securities
remaining available for
future issuance under
equity compensation
plans (excluding securities
reflected in column (a))
|
|
|
|
(a)
|
|
(b)
|
|
(c)
|
|
Equity compensation plans approved by security holders (1)
|
|
|
934,112
|
|
$
|
28.67
|
|
|
2,000,226
|
(2)(3)(4)
|
Equity compensation plans not approved by security holders
|
|
|
|
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
934,112
|
|
$
|
28.67
|
|
|
2,000,226
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
(1)
-
Includes
shares of our Common Stock issuable upon exercise of options under our 2006 Equity Participation Plan and our 2012 Incentive Award Plan.
-
(2)
-
These
shares are available for future issuance under our 2012 Incentive Award Plan, which was approved by our shareholders on December 12, 2012. Upon
shareholder approval of the 2012 Incentive Award Plan, we froze the 2006 Equity Participation Plan, and no further awards can be granted thereunder.
-
(3)
-
Awards
of restricted stock, restricted stock units or other awards that convey the full value of the shares subject to the award are counted as 1.87 shares
for every one award granted.
-
(4)
-
Shares
subject to awards outstanding under the 2006 Equity Participation Plan that terminate, expire or lapse for any reason (up to a maximum of 2,220,000
shares) also become available for future issuance under our 2012 Incentive Award Plan.
55
Table of Contents
Performance Graph
The graph below compares the cumulative total stockholder return for the period beginning on the market close on the last trading day
before the beginning of our fifth preceding fiscal year through and including the end of our last completed fiscal year with (a) The NASDAQ Composite Index and (b) a peer group of
publicly-traded issuers with which we have generally competed.
The
peer group includes the following companies: American Science & Engineering (NASDAQ Symbol: ASEI) and Analogic Corporation (NASDAQ Symbol: ALOG).
The
graph assumes that $100.00 was invested on June 30, 2011in (a) our Common Stock, (b) The NASDAQ Composite Index and (c) the companies comprising the peer
group described above (weighted according to each respective issuer's stock market capitalization at the beginning of each period for which a return is indicated). The graph assumes that all dividends
were reinvested. Historical stock price performance is not necessarily indicative of future stock price performance.
This
performance graph shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or incorporated by reference into any Company filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Comparison of 5 Year Cumulative Total Return
Assumes Initial Investment of $100
June 2011 through June 2016
Among OSI Systems, Inc.
The NASDAQ Composite Index and a Peer Group
The
following table provides the same information in tabular form as of June 30:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2011
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
OSI Systems, Inc.
|
|
$
|
100.00
|
|
$
|
147.30
|
|
$
|
149.81
|
|
$
|
155.23
|
|
$
|
164.63
|
|
$
|
135.19
|
|
The NASDAQ Composite Index
|
|
|
100.00
|
|
|
108.58
|
|
|
128.19
|
|
|
169.08
|
|
|
192.10
|
|
|
187.57
|
|
Peer Group
|
|
|
100.00
|
|
|
94.42
|
|
|
105.64
|
|
|
121.04
|
|
|
107.01
|
|
|
105.60
|
|
56
Table of Contents
ITEM 6. SELECTED FINANCIAL DATA
The following tables set forth our selected consolidated financial data as of and for each of the five fiscal years ended
June 30, 2016, and is derived from our consolidated financial statements. The consolidated financial statements as of June 30, 2015 and 2016, and for each of the years in the three-year
period ended June 30, 2016, are included elsewhere in this report. The following data should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results
of Operations" and the consolidated financial statements and notes thereto included elsewhere in this report.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended June 30,
|
|
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
|
|
(in thousands, except earnings per share data)
|
|
Consolidated Statements of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
$
|
792,990
|
|
$
|
802,047
|
|
$
|
906,742
|
|
$
|
958,202
|
|
$
|
829,660
|
|
Cost of goods sold
|
|
|
524,348
|
|
|
511,621
|
|
|
601,742
|
|
|
632,849
|
|
|
552,801
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
268,642
|
|
|
290,426
|
|
|
305,000
|
|
|
325,353
|
|
|
276,859
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative
|
|
|
151,746
|
|
|
159,761
|
|
|
166,869
|
|
|
171,756
|
|
|
166,655
|
|
Research and development
|
|
|
49,565
|
|
|
48,240
|
|
|
44,792
|
|
|
51,639
|
|
|
49,816
|
|
Impairment, restructuring and other charges
|
|
|
1,391
|
|
|
7,987
|
|
|
12,044
|
|
|
9,850
|
|
|
22,014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
202,702
|
|
|
215,988
|
|
|
223,705
|
|
|
233,245
|
|
|
238,485
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations
|
|
|
65,940
|
|
|
74,438
|
|
|
81,295
|
|
|
92,108
|
|
|
38,374
|
|
Interest and other expense, net
|
|
|
(3,957
|
)
|
|
(5,024
|
)
|
|
(5,440
|
)
|
|
(3,255
|
)
|
|
(2,879
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
|
61,983
|
|
|
69,414
|
|
|
75,855
|
|
|
88,853
|
|
|
35,495
|
|
Provision for income taxes
|
|
|
16,435
|
|
|
25,279
|
|
|
27,961
|
|
|
23,702
|
|
|
9,338
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
45,548
|
|
$
|
44,135
|
|
$
|
47,894
|
|
$
|
65,151
|
|
$
|
26,157
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income available to common stockholdersdiluted
|
|
$
|
45,548
|
|
$
|
44,135
|
|
$
|
47,894
|
|
$
|
65,151
|
|
$
|
26,157
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per common share
|
|
$
|
2.31
|
|
$
|
2.21
|
|
$
|
2.40
|
|
$
|
3.29
|
|
$
|
1.35
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per common share
|
|
$
|
2.24
|
|
$
|
2.15
|
|
$
|
2.33
|
|
$
|
3.17
|
|
$
|
1.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstandingdiluted
|
|
|
20,330
|
|
|
20,568
|
|
|
20,587
|
|
|
20,526
|
|
|
20,076
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended June 30,
|
|
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
|
|
(in thousands)
|
|
Consolidated Balance Sheet Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
91,452
|
|
$
|
34,697
|
|
$
|
38,831
|
|
$
|
47,593
|
|
$
|
104,370
|
|
Working capital
|
|
|
322,464
|
|
|
244,885
|
|
|
263,514
|
|
|
254,991
|
|
|
187,483
|
|
Total assets
|
|
|
749,896
|
|
|
952,739
|
|
|
1,011,077
|
|
|
937,289
|
|
|
991,723
|
|
Long-term debt
|
|
|
2,467
|
|
|
10,673
|
|
|
10,436
|
|
|
8,556
|
|
|
6,054
|
|
Total debt
|
|
|
2,682
|
|
|
71,470
|
|
|
37,255
|
|
|
11,357
|
|
|
133,813
|
|
Total stockholders' equity
|
|
|
434,119
|
|
|
478,451
|
|
|
532,213
|
|
|
581,779
|
|
|
540,846
|
|
57
Table of Contents
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
We are a vertically integrated designer and manufacturer of specialized electronic systems and components for critical applications. We
sell our products and provide related services in diversified markets, including homeland security, healthcare, defense and aerospace. We have three operating divisions: (a) Security, providing
security and inspection systems and turnkey security screening solutions; (b) Healthcare, providing patient monitoring, diagnostic cardiology, anesthesia systems and defibrillator products; and
(c) Optoelectronics and Manufacturing, providing specialized electronic components for our Security and Healthcare divisions, as well as to third parties for applications in the defense and
aerospace markets, among others.
Security Division.
Through our Security division, we provide security screening products and services worldwide, as well as
turnkey security
screening solutions. These products and services are used to inspect baggage, parcels, cargo, people, vehicles and other objects for weapons, explosives, drugs, radioactive and nuclear materials and
other contraband. Revenues from our Security division accounted for 50% of our total consolidated revenues for fiscal 2016.
As
a result of the terrorist attacks in the U.S. and in other locations worldwide, security and inspection products have increasingly been used at a wide range of facilities other than
airports, such as border crossings, railways, seaports, cruise line terminals, freight forwarding operations, sporting venues, government and military installations and nuclear facilities. We believe
that our wide-ranging product portfolio together with our ability to provide turnkey screening solutions position us to competitively pursue security and inspection opportunities as they arise
throughout the world.
Currently,
the U.S. federal government is discussing various options to address sequestration and the U.S. federal government's overall fiscal challenges and we cannot predict the
outcome of these efforts. While we believe that national security spending will continue to be a priority, U.S. government budget deficits and the national debt have created increasing pressure to
examine and reduce spending across many federal agencies. Additionally, there continues to be volatility in international markets that has impacted international security spending. We believe that the
diversified product portfolio and international customer mix of our Security division position us well to withstand the impact of these uncertainties and even benefit from specific initiatives within
various governments. However, depending on how future sequestration cuts are implemented and how the U.S. federal government and our other international customers manage their fiscal challenges, we
believe that these actions could have a material, adverse effect on our business, financial condition and results of operations.
Healthcare Division.
Through our Healthcare division, we design, manufacture, market and service patient monitoring, cardiology,
anesthesia delivery
and ventilation systems and defibrillator products worldwide for
sale primarily to hospitals and medical centers. Our products monitor patients in critical, emergency and perioperative care areas of the hospital and provide information, through wired and wireless
networks, to physicians and nurses who may be at the patient's bedside, in another area of the hospital or even outside the hospital. Revenues from our Healthcare division accounted for 25% of our
total consolidated revenues for fiscal 2016.
The
healthcare markets in which we operate are highly competitive. We believe that our customers choose among competing products on the basis of product performance, functionality, value
and service. There is continued uncertainty regarding the U.S. federal government budget and the Affordable Care Act, either of which may impact hospital spending, third-party payer reimbursement and
fees to be levied on certain medical device revenues, any of which could adversely affect our business and results of operations. In addition, hospital capital spending appears to have been impacted
by strategic uncertainties surrounding the Affordable Care Act and economic pressures. We also believe that global economic uncertainty has caused some hospitals and healthcare providers to delay
purchases of our products and services. During this period of uncertainty, sales of our healthcare
58
Table of Contents
products
may be negatively impacted. We cannot predict when the markets will fully recover or when the uncertainties related to the U.S. federal government will be resolved and, therefore, when this
period of delayed and diminished purchasing will end. A prolonged delay could have a material adverse effect on our business, financial condition and results of operations.
Optoelectronics and Manufacturing Division.
Through our Optoelectronics and Manufacturing division, we design, manufacture and
market optoelectronic
devices and provide electronics manufacturing services globally for use in a broad range of applications, including aerospace and defense electronics, security and inspection systems, medical imaging
and diagnostics, telecommunications, office automation, computer peripherals, industrial automation, automotive diagnostic systems, gaming systems and consumer products. We also provide our
optoelectronic devices and electronics manufacturing services to original equipment manufacturers ("OEM") customers, as well as our own Security and Healthcare divisions. Revenues from external
customers in our Optoelectronics and Manufacturing division accounted for approximately 25% of our total consolidated revenues for fiscal 2016.
Fiscal 2016 Compared with Fiscal 2015.
We reported consolidated operating profit of $38.4 million for fiscal 2016, a
$53.7 million, or
58%, decrease from the $92.1 million operating profit reported for fiscal 2015. This decline in profitability was driven primarily by a 13% decrease in sales, which was the primary driver of a
$48.5 million decrease in gross profit, and a $12.1 million increase in impairment, restructuring and other charges. These factors were partially offset by a $5.1 million decrease
in SG&A expenses and a $1.8 million decrease in research and development.
Fiscal 2015 Compared with Fiscal 2014.
We reported consolidated operating profit of $92.1 million for fiscal 2015, a
$10.8 million, or
13%, improvement over the $81.3 million operating profit reported for fiscal 2014. This improved profitability was driven primarily by a 6% increase in sales, which was the primary driver of a
$20.4 million increase in gross profit, and a $2.2 million decrease in impairment, restructuring and other charges. These factors were partially offset by a $4.9 million increase
in SG&A expenses to support our growth and a $6.8 million increase in research and development to support and expand our product portfolio.
Acquisitions.
Historically, an active acquisition program has been an important element of our corporate strategy. Over the past
three years, none of
our acquisitions has been considered materially significant, either individually or in the aggregate. We continue to believe that an active acquisition program supports our long-term strategic goals
and we intend to look to acquisitions to strengthen our competitive position, expand our customer base and augment our considerable research and development programs. Through such efforts we aim to
accelerate innovation, improve earnings and increase overall stockholder value. As discussed in more detail under "Item 1. BusinessRecent DevelopmentsPending
Acquisition of AS&E," we have entered into a definitive agreement to acquire AS&E. We intend to fund the transaction with a combination of cash on hand and money borrowed under our revolving credit
facility, and expect the transaction, which is subject to customary closing conditions, to close by December 31, 2016.
Trends and Uncertainties
The following is a discussion of certain trends and uncertainties that we believe have and may continue to influence our results of
operations.
Global Economic Considerations.
The recent slowdown in the China economy, which has created global economic uncertainty, coupled
with the strength of
the U.S. dollar, which may make our products and services less competitive in countries with currencies that have declined in value against the U.S. dollar, has continued to negatively impact demand
for certain of our products and services in our Security and Healthcare divisions.
59
Table of Contents
Additionally,
weakness in the oil markets has led to delayed purchasing by certain customers generally within the security industry impacting our Security division but also in other industries
impacting our other two divisions. It is uncertain how long the period of economic uncertainty in China or the impact of lower oil prices will last. Therefore, we expect that there may continue to be
a period of delayed or deferred purchasing by our customers, but we are unable to quantify the magnitude of the potential impact at this time. Purchase delays and deferments could continue to have a
material negative effect on demand for our products and services, and accordingly, on our business, results of operations and financial condition.
Healthcare Product Introductions.
The results of our operations have been adversely impacted by issues associated with
significant product launches
within our Healthcare division. Although we are hopeful that the challenges associated with these product launches will be resolved in the near future, the resultant delays may continue to adversely
impact our results of operations for additional periods.
European Union Threat Detection Standards.
The European Union has implemented regulations for all airports within the EU to have
hold baggage
screening systems that are compliant with the European Civil Aviation Conference (ECAC) Standard 3 beginning in 2020. However, this deadline could potentially be delayed. Our Security division's RTT
product has passed the ECAC explosive detection system Standard 3 threat detection requirement.
Critical Accounting Policies and Estimates
The following discussion and analysis of our financial condition and results of operations is based on our consolidated financial
statements, which have been prepared in conformity with accounting principles generally accepted in the United States. Our preparation of these consolidated financial statements requires us to make
judgments and estimates that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. As a
result, actual results may differ from such estimates. Our senior management has reviewed these critical accounting policies and related disclosures with the Audit Committee of our Board of Directors.
The following summarizes our critical accounting policies and significant estimates used in preparing our consolidated financial statements:
Revenue Recognition.
We recognize revenue from sales of products upon shipment when title and risk of loss passes, and when terms
are fixed and
collection is probable. Revenue from services includes after-market services, installation and implementation of products, and turnkey security screening services. Generally, revenue from services is
recognized when the services are performed. The portion of revenue for the sale attributable to installation is deferred and recognized when the installation service is provided. In an instance where
terms of sale include subjective customer acceptance criteria, revenue is deferred until we have achieved the acceptance criteria. Concurrent with the revenue recognition, we accrue estimated product
return reserves and warranty expenses. Critical judgments made by management related to revenue recognition include the determination of whether or not customer acceptance criteria are perfunctory or
inconsequential. The determination of whether or not customer acceptance terms are perfunctory or inconsequential impacts the amount and timing of revenue recognized. Critical judgments also include
estimates of warranty reserves, which are established based on historical experience and knowledge of the product under warranty. In instances where a contract calls for multiple deliverables and such
deliverables qualify as separate units of accounting, we may recognize revenue based on the value of the respective deliverables identified in the underlying contract.
In
connection with the agreement with the Servicio de Administración Tributaria ("SAT") in Mexico, revenue is recognized based upon proportional performance, measured by
the actual number of labor hours incurred divided by the total estimated number of labor hours for the project. The impact of changes in the estimated labor hours to service the agreement is reflected
in the period during which the change becomes known. In the SAT agreement,
60
Table of Contents
customer
billings may be submitted for several separate deliverables including: monthly services, activation of services, training of customer personnel and consultation on the design and location of
security scanning operations, among others. In the event that payments received from the customer exceed revenue recognition, deferred revenue is recorded. In the event that revenue recognition
exceeds payments received from the customer, unbilled receivables are recorded.
Revenues
from out-of-warranty service maintenance contracts are recognized ratably over the term of such contracts. For services not derived from specific maintenance contracts, revenues
are recognized as the services are performed. Deferred revenue for such services arises from payments received from customers for services not yet performed. On occasion, we receive advances from
customers that are amortized against future customer payments pursuant to the underlying agreements. Such advances are classified in the consolidated balance sheets as either a current or long-term
liability depending on when we estimate the corresponding amortization to occur.
Allowance for Doubtful Accounts.
The allowance for doubtful accounts involves estimates based on management's judgment, review
of individual
receivables and analysis of historical bad debts. We monitor collections and payments from our customers and we maintain allowances for doubtful accounts for estimated losses resulting from the
inability of our customers to make required payments. We also assess current economic trends that might impact the level of credit losses in the future. If the financial condition of our customers
were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances could be required.
Inventory.
Inventory is stated at the lower of cost or market. Cost is determined on the first-in, first-out method. We write
down inventory for
slow-moving and obsolete inventory based on assessments of future demands, market conditions and customers who may be experiencing financial difficulties. If these factors were to become less
favorable than those projected, additional inventory write-downs could be required.
Property and Equipment.
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation
and amortization are
charged while assets are used in service and are computed using the straight-line method over the estimated useful lives of the assets taking into consideration any estimated salvage value.
Amortization of leasehold improvements is calculated on the straight-line method over the shorter of the useful life of the asset or the lease term. Leased capital assets are included in property and
equipment. Amortization of property and equipment under capital leases is included with depreciation expense. In the event that property and equipment are idle, as a result of excess capacity or the
early
termination, non-renewal or reduction in scope of a turnkey screening operation, such assets are assessed for impairment on a periodic basis and when an indication that impairment may exist.
Income Taxes.
Our annual tax rate is based on our income, statutory tax rates and tax planning opportunities available to us in
the various
jurisdictions in which we operate. Tax laws are complex and subject to different interpretations by the taxpayer and respective governmental taxing authorities. Significant judgment is required in
determining our tax expense and in evaluating our tax positions including evaluating uncertainties. We review our tax positions quarterly and adjust the balances as new information becomes available.
Deferred
income tax assets represent amounts available to reduce income taxes payable on taxable income in future years. Such assets arise because of temporary differences between the
financial reporting and tax bases of assets and liabilities, as well as from net operating loss and tax credit carryforwards. We evaluate the recoverability of these future tax deductions by assessing
the adequacy of future expected taxable income from all sources, including reversal of taxable temporary differences, forecasted operating earnings and available tax planning strategies. These sources
of income inherently rely on estimates. To provide insight, we use our historical experience and our short and long-range business forecasts. We believe it is more likely than not that a portion of
the deferred income tax assets may expire unused and therefore have established a valuation allowance against them. Although realization is not assured for the remaining deferred income tax assets, we
believe it is more likely than not that the deferred tax assets will be fully recoverable within the applicable statutory expiration periods.
61
Table of Contents
However,
deferred tax assets could be reduced in the near term if our estimates of taxable income are significantly reduced or available tax planning strategies are no longer viable.
Business Combinations.
We allocate the fair value of purchase consideration to the tangible and intangible assets acquired, and
liabilities assumed
based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations
require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited
to, future expected cash flows from acquired customers, acquired technology, and trade names, useful lives and discount rates. Our estimates of fair value are based upon assumptions believed to be
reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. During the measurement period, which is one year from the acquisition date,
the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments
are recorded to earnings.
Impairment of Long-Lived Assets.
Goodwill represents the excess purchase price of net tangible and intangible assets acquired in
business
combinations over their estimated fair value. Goodwill is allocated to our segments based on the nature of the product line of the acquired business. The carrying value of goodwill is not amortized,
but is annually tested for impairment during our second quarter and more often if there is an indicator of impairment. Intangible assets other than goodwill are amortized over their useful lives
unless these lives are determined to be indefinite.
We
assess qualitative factors of each of our reporting units to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount,
including goodwill. Such assessments indicated that it is not more likely than not that the fair value of each reporting unit is less than its carrying amount, including goodwill. Thus, we have
determined that it is not necessary to proceed with the two-step goodwill impairment test. There was no goodwill impairment for each of the three fiscal years ended June 30, 2016. We evaluate
long-lived assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Impairment is considered to exist
if the total estimated future cash flows on an undiscounted basis are less than the carrying amount of the assets. If impairment does exist, we measure the impairment loss and record it based on the
discounted estimate of future cash flows. In estimating future cash flows, we group assets at the lowest level for which there are identifiable cash flows that are largely independent of the cash
flows from other asset groups. Our estimate of future cash flows is based upon, among other things, certain assumptions about expected future operating performance, growth rates and other factors.
Although
we believe the assumptions and estimates we have made in the past have been reasonable and appropriate, different assumptions and estimates could materially impact our reported
financial results. More conservative estimates of the anticipated future benefits from these businesses could result in impairment charges, which would decrease net income and result in lower asset
values on our balance sheet.
Stock-Based Compensation Expense.
We account for stock-based compensation using fair value recognition provisions. Thus, we
record stock-based
compensation as a charge to earnings net of the estimated impact of forfeited awards. As such, we recognize stock-based compensation cost only for those stock-based awards that are estimated to
ultimately vest over their requisite vesting period, based on the vesting provisions of the individual grants.
The
process of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over their requisite vesting period involves significant
assumptions and judgments. We estimate the fair value of stock option awards on the date of grant using the Black-Scholes option-valuation model which requires that we make certain assumptions
regarding: (i) the expected volatility in the market price of our Common Stock; (ii) dividend yield; (iii) risk-free interest rates; and (iv) the period of time employees
are expected to hold the
62
Table of Contents
award
prior to exercise. We estimate the fair value of restricted stock and restricted stock unit awards on the date of the grant using the market price of our Common Stock on that date. In addition,
we are required to estimate the expected impact of forfeited awards and recognize stock-based compensation cost only for those awards expected to vest. If actual forfeiture rates differ materially
from our estimates, stock-based compensation expense could differ significantly from the amounts we have recorded in the current period. We periodically review actual forfeiture experience and revise
our estimates, as necessary. We recognize the cumulative effect of changes in the estimated forfeiture rate as compensation cost in earnings in the period of the revision. As a result, if we revise
our assumptions and estimates, our stock-based compensation expense could change materially in the future. Certain shares of restricted stock and restricted stock units vest based upon the achievement
of pre-established performance criteria. We estimate the fair value of performance-based awards at the date of grant based upon the probability that the specified performance criteria will be met,
adjusted for estimated forfeitures. Each quarter we update our assessment of the probability that the specified performance criteria will be achieved and adjust our estimate of the fair value of the
performance-based awards if necessary. We amortize the fair values of performance-based awards over the requisite service period adjusted for estimated forfeitures for each separately vesting tranche
of the award. See note 7 to the consolidated financial statements for a further discussion of stock-based compensation.
Legal and Other Contingencies.
We are subject to various claims and legal proceedings. We review the status of each significant
legal dispute to
which we are a party and assess our potential financial exposure, if any. If the potential financial exposure from any claim or legal proceeding is considered probable and the amount can be reasonably
estimated, we record a liability and an expense for the estimated loss. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is
reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess
the potential liability related to our pending claims and litigation and revise our estimates accordingly. Such revisions in the estimates of the potential liabilities could have a material impact on
our results of operations and financial position.
Net Revenues
The table below and the discussion that follows are based upon the way we analyze our business. See note 13 to the consolidated
financial statements for additional information about business segments.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2014
|
|
% of
Net Sales
|
|
2015
|
|
% of
Net Sales
|
|
2016
|
|
% of
Net Sales
|
|
2014-2015
% Change
|
|
2015-2016
% Change
|
|
|
|
(Dollars in millions)
|
|
Security
|
|
$
|
440.4
|
|
|
49
|
%
|
$
|
481.1
|
|
|
50
|
%
|
$
|
411.2
|
|
|
50
|
%
|
|
9
|
%
|
|
(15
|
)%
|
Healthcare
|
|
|
222.3
|
|
|
24
|
%
|
|
255.7
|
|
|
27
|
%
|
|
211.5
|
|
|
25
|
%
|
|
15
|
%
|
|
(17
|
)%
|
Optoelectronics / Manufacturing
|
|
|
244.0
|
|
|
27
|
%
|
|
221.4
|
|
|
23
|
%
|
|
207.0
|
|
|
25
|
%
|
|
(9
|
)%
|
|
(7
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Net Revenues
|
|
$
|
906.7
|
|
|
|
|
$
|
958.2
|
|
|
|
|
$
|
829.7
|
|
|
|
|
|
6
|
%
|
|
(13
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal 2016 Compared with Fiscal 2015.
Revenues for the Security division decreased 15% primarily as a result of a
$66.4 million reduction in
revenues associated with a Foreign Military Sale contract with the U.S. Department of Defense ("FMS Contract") as compared to the prior year. The delivery of equipment under the FMS Contract was
completed in fiscal 2015, and revenues during the remainder of the contract, which expires in fiscal 2017, are not expected to be significant. This decrease was partially offset by revenues from the
commencement of our turnkey scanning operation in Albania during the year.
Revenues
for the Healthcare division decreased across the bulk of our product lines and regions. We believe this contraction is due, in part, to a hospital spending environment adversely
impacted by challenging economic environments in many of our markets and lapses in operational execution.
63
Table of Contents
Revenues
for the Optoelectronics and Manufacturing division decreased in fiscal 2016 primarily as a result of a $26.8 million decrease in organic sales in our contract
manufacturing business due to a reduction in unit volume purchases from our OEM customers, including an $11.5 million year-over-year reduction in sales to a
single large customer to whom we still sell. This decrease in organic sales was partially offset by $8.8 million of revenues from two small contract manufacturing businesses that were acquired
during the third quarter of fiscal 2016.
Fiscal 2015 Compared with Fiscal 2014.
Revenues for the Security division increased 9% primarily as a result of increased
baggage and parcel
inspection and cargo sales, new product launches and $48.0 million of incremental revenue from an FMS Contract awarded in the fourth quarter of fiscal 2014 to supply multiple units of cargo and
vehicle inspection systems and related training, spare parts, service and logistics support for Iraq. These increases were partially offset by a decrease in sales of other products and services.
Revenues
for the Healthcare division increased 15% primarily as a result of a 14% increase in sales in North America as sales in the U.S. and Canada improved significantly, an 11%
increase in Latin American and Asian markets, and the impact of an acquisition of a European cardiology equipment business during the first quarter of fiscal 2015, which drove 8% of the division's
growth. The increase in organic sales primarily occurred within our patient monitoring product line due to the domestic market improvement and the success of new product introductions. These increases
were partially offset by a decrease in organic sales in our Europe, Middle East and African regions.
Revenues
for the Optoelectronics and Manufacturing decreased 9% as a result of lower contract manufacturing sales in fiscal 2015. This decrease was primarily attributable to a difficult
comparable in the prior year resulting from significant sales to two customers to whom we continue to sell but at a lower level. Increased sales within our commercial optoelectronics business
partially offset this decrease.
Gross Profit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2014
|
|
% of
Net Sales
|
|
2015
|
|
% of
Net Sales
|
|
2016
|
|
% of
Net Sales
|
|
|
|
(Dollars in millions)
|
|
Gross profit
|
|
$
|
305.0
|
|
|
33.6
|
%
|
$
|
325.4
|
|
|
34.0
|
%
|
$
|
276.9
|
|
|
33.4
|
%
|
Fiscal 2016 Compared with Fiscal 2015.
Gross profit decreased 15% primarily as a result of the 13% decrease in sales. Gross
margin decreased due to
lower sales within our Healthcare division, which carries the highest gross margin of our three divisions, and an unfavorable product mix within our Security division. These factors were partially
offset by improved gross margin within our Optoelectronics and Manufacturing division due to a more favorable product mix.
Fiscal 2015 Compared with Fiscal 2014.
Gross profit increased 7% primarily as a result of the 6% increase in sales. Our gross
margin during fiscal
2015 increased to 34.0% from 33.6% for the prior year. The increase was attributable to: (i) the impact of increased revenue from our Healthcare division, which grew faster than our other two
divisions, and which historically generates the highest gross margins across the three divisions; and (ii) the impact of a reduction in revenues in our Optoelectronics and Manufacturing
division, which historically generates the lowest gross margin across the three divisions. These factors were partially offset by increased depreciation associated with our turnkey operations in the
Security division.
64
Table of Contents
Operating Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2014
|
|
% of
Net Sales
|
|
2015
|
|
% of
Net Sales
|
|
2016
|
|
% of
Net Sales
|
|
2014-2015
% Change
|
|
2015-2016
% Change
|
|
|
|
(Dollars in millions)
|
|
Selling, general and administrative
|
|
$
|
166.9
|
|
|
18.4
|
%
|
$
|
171.8
|
|
|
17.9
|
%
|
$
|
166.7
|
|
|
20.1
|
%
|
|
3
|
%
|
|
(3
|
)%
|
Research and development
|
|
|
44.8
|
|
|
4.9
|
%
|
|
51.6
|
|
|
5.4
|
%
|
|
49.8
|
|
|
6.0
|
%
|
|
15
|
%
|
|
(3
|
)%
|
Impairment, restructuring and other charges
|
|
|
12.0
|
|
|
1.3
|
%
|
|
9.8
|
|
|
1.0
|
%
|
|
22.0
|
|
|
2.7
|
%
|
|
(18
|
)%
|
|
124
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
$
|
223.7
|
|
|
24.7
|
%
|
$
|
233.2
|
|
|
24.3
|
%
|
$
|
238.5
|
|
|
28.7
|
%
|
|
4
|
%
|
|
2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, General and Administrative
SG&A expenses consisted primarily of compensation paid to sales, marketing and administrative personnel, professional service fees and
marketing expenses.
Fiscal 2016 Compared with Fiscal 2015.
For fiscal 2016, SG&A expenses decreased by 3% primarily due to a reduction in
variable compensation as a
result of lower sales, and a $5.8 million increase in the revaluation of contingent acquisition obligations, which reduced SG&A expenses, compared to the prior year. As a percentage of revenue,
SG&A expenses were 20.1% for fiscal 2016, compared to 17.9% for the comparable prior year.
Fiscal 2015 Compared with Fiscal 2014.
For fiscal 2015, SG&A expenses increased by 3% to support our 6% revenue growth. This
increased spending was
partially offset by a $5.0 million increase in the revaluation of contingent acquisition obligations, which reduced SG&A expenses, compared to the prior year. As a percentage of revenue, SG&A
expenses were 17.9% for fiscal 2015, compared to 18.4% for the comparable prior year.
Research and Development
Our Security and Healthcare divisions have historically invested substantial amounts in R&D. We intend to continue this trend in future
years, although specific programs may or may not continue to be funded and funding levels may fluctuate. R&D expenses included research related to new product development and product enhancement
expenditures.
Fiscal 2016 Compared with Fiscal 2015.
R&D spending in fiscal 2016 was generally consistent with the prior year.
Fiscal 2015 Compared with Fiscal 2014.
R&D spending in fiscal 2015 increased by 15% over the prior year as a result of
increased investment in the
next generation of products within our Security division. This increase was partially offset by a decrease in spending within our Healthcare division.
Impairment, Restructuring and Other Charges
For the past several years we have endeavored to align our global capacity and infrastructure with demand by our customers and fully
integrate acquisitions, thereby improving our operational efficiency. These activities included reducing excess workforce and capacity, consolidating and relocating certain manufacturing facilities
and reviewing the value of certain technologies and product lines. The overall objectives of the restructuring activities were to lower costs and better utilize our existing manufacturing capacity.
During fiscal 2014 through 2016, we continued these efforts to further increase operating efficiencies. Our efforts have helped enhance our ability to improve operating margins, retain and expand
existing relationships with customers and attract new business. We may utilize similar measures in the future to realign our operations to further increase our operating efficiencies. The effect of
these efforts may materially affect our future operating results.
65
Table of Contents
Fiscal 2016 Compared with Fiscal 2015.
During fiscal 2016, we incurred $22.0 million of impairment, restructuring and other
charges primarily
as follows: (i) $5.2 million related to facility consolidations and severance; (ii) the $6.8 million impairment of certain fixed assets and technology we believe are no
longer usable or saleable; (iii) $3.7 million of costs related to acquisitions; (iv) the write off of a $2.8 million minority investment that we believe is permanently
impaired; (v) $2.9 million related to legal settlements and related legal costs; and (vi) $0.6 million of other costs.
Fiscal 2015 Compared with Fiscal 2014.
During fiscal 2015, we incurred $9.8 million of impairment, restructuring and other
charges as follows:
(i) $5.4 million related to facility consolidations and severance; (ii) $3.8 million of costs incurred within our Security division related to contract issues with the U.
S. federal government; and (iii) $0.7 million of professional fees associated with defending the Securities Class Action and Derivative Actions, which were recorded in our Corporate
segment.
Interest and Other Expense, net
Interest and other expense, net includes interest expense related to our credit facility and other debt, the impact of foreign currency
forward contracts that were not treated as cash flow hedges and other non-operating expense and income items.
Fiscal 2016 Compared with Fiscal 2015.
In fiscal 2016, our interest and other expense, net was $2.9 million, compared to
$3.3 million
in fiscal 2015. Interest expense associated with higher levels of borrowing under our revolving credit facility in the current fiscal year was offset by a significant reduction in outstanding letters
of credit under the credit facility.
Fiscal 2015 Compared with Fiscal 2014.
In fiscal 2015, our interest and other expense, net was $3.3 million, compared to
$5.4 million
in fiscal 2014. This decrease was due to decreased interest expense related to lower average outstanding borrowings and lower average outstanding letters of credit under our revolving credit facility,
and the reduction in the cost of borrowing in connection with the amended credit facility completed in May 2014.
Provision for Income Taxes
The effective tax rate for a particular period varies depending on a number of factors including (i) the mix of income earned in
various tax jurisdictions, each of which applies a unique range of income tax rates and income tax credits, (ii) changes in previously established valuation allowances for deferred tax assets
(changes are based upon our current analysis of the likelihood that these deferred tax
assets will be realized), (iii) the level of non-deductible expenses, (iv) certain tax elections and (v) tax holidays granted to certain of our international subsidiaries.
Fiscal 2016 Compared with Fiscal 2015.
In fiscal 2016, our income tax expense was $9.3 million, compared to
$23.7 million for fiscal
2015, resulting in an effective tax rate of 26.3% in fiscal 2016 as compared to a tax rate of 26.7% in fiscal 2015.
Fiscal 2015 Compared with Fiscal 2014.
In fiscal 2015, our income tax expense was $23.7 million, compared to
$28.0 million for fiscal
2014, resulting in an effective tax rate of 26.7% in fiscal 2015 and 36.9% in fiscal 2014. Included within the fiscal 2014 expense was a non-cash tax charge of $7.6 million as a result of
electing to accelerate the tax depreciation of certain fixed assets related to our turnkey screening solutions program in Mexico. This election resulted in cash tax savings of approximately
$21 million in fiscal 2014. However, portions of the tax bases of the underlying assets were forfeited resulting in a non-cash tax charge in the year the election was made. Excluding the impact
of this charge, our effective tax rate would have been 26.8% in fiscal 2014.
66
Table of Contents
Liquidity and Capital Resources
Our principal sources of liquidity are our cash and cash equivalents, cash generated from operations and our credit facility. Cash and
cash equivalents totaled $104.4 million at June 30, 2016, an increase of $56.8 million, or 119%, from $47.6 million at June 30, 2015. During fiscal 2016, we
generated $59.2 million of cash flow from operations. These proceeds, in addition to borrowings from our credit facility, were used for the following: $17.7 million invested in capital
expenditures, $19.9 million for the acquisition of businesses and other assets and $87.1 million for the repurchase of our common stock, including net share settlement of equity awards.
If we continue to net settle equity awards, we will use additional cash to pay our tax withholding obligations in connection with such settlements. We currently anticipate that our available funds,
credit facilities and cash flow from operations will be sufficient to meet our operational cash needs for the foreseeable future. In addition, without repatriating earnings from non-U.S. subsidiaries,
we anticipate that cash generated from operations will be able to satisfy our obligations in the U.S., including our outstanding lines of credit, as accounting earnings in the U.S. are not necessarily
indicative of cash flows since earnings are generally reduced by non-cash expenses including depreciation, amortization, and stock-based compensation.
We
have a five-year revolving credit facility that allows us to borrow up to $450 million at London Interbank Offered Rate ("LIBOR") plus 1.25% depending upon our leverage ratio.
As of June 30, 2016, there was $125 million outstanding under the revolving credit facility and letters-of-credit outstanding totaled $6.2 million. As discussed in more detail
under "Item 1. BusinessRecent DevelopmentsPending Acquisition of AS&E," we have entered into a definitive agreement to acquire AS&E. The total purchase price is
approximately $269 million. We expect to fund the transaction with a combination of AS&E's cash on hand and money borrowed under the revolving credit facility. As of June 30, 2016, AS&E
reported cash and cash equivalents of $74 million.
Cash Provided by Operating Activities.
Cash flows from operating activities can fluctuate significantly from period to period,
as net income,
adjusted for non-cash items, and working capital fluctuations impact cash flows. During fiscal 2016, we generated cash from operations of $59.2 million compared to $105.1 million in the
prior-year period. The principal drivers of the reduced cash flow in the current year were lower profits and increased inventory levels. This increase in inventory was primarily driven by the
continued build up to support expected sales in our Security division, as well as increased inventory in our Healthcare division as significantly higher sales in this division were anticipated during
the second half of the year. In addition, this increase in inventory includes a significant amount of inventory that was shipped to Security division customers for which revenue is expected to be
recognized in future quarters.
Cash
flow from operating activities during fiscal 2016 primarily consisted of net income of $26.2 million, adjusted for certain non-cash items, including total depreciation and
amortization of $57.9 million, stock-based compensation expense of $20.8 million and impairment charges of $9.7 million, and was offset by deferred taxes of $13 million and
the net impact of changes in operating assets and liabilities on cash of $44.6 million.
Cash Used in Investing Activities.
Net cash used in investing activities was $43.5 million during fiscal 2016 as compared
to
$35.4 million used during the prior year. The changes in cash flows from investing activities were primarily related to acquisition of businesses, and investments in capital expenditures and
other assets to support our growth plans. During fiscal 2016, we used cash of $19.9 million for acquisitions of businesses as compared to $13.9 million in the comparable prior year
period. During fiscal 2016, we made $17.7 million in capital expenditures compared to $15.3 million during the prior-year period.
Cash Provided by (Used in) Financing Activities.
Net cash provided by financing activities was $41.8 million during fiscal
2016, compared to
$60.0 million used in financing activities during the prior year. The changes in cash flows from financing activities primarily relate to (i) borrowings and payments under debt
obligations; (ii) the issuance of and/or repurchase of Common Stock and (iii) employee stock plan activities. During fiscal 2016, we borrowed $125.0 million from our revolving
credit facility as compared to repayment of $24.0 million in the prior year. This increased borrowing was partly done in part in lieu of repatriating funds from
67
Table of Contents
foreign
tax jurisdictions to enable the repurchase of $87.1 million of our Common Stock, including net share settlement of equity awards during fiscal 2016, as compared to $37.9 million
for the same period in the prior year.
Borrowings
Outstanding lines of credit and current and long-term debt totaled $133.8 million at June 30, 2016, an increase of
$122.4 million from $11.4 million at June 30, 2015. See note 6 to the consolidated financial statements for further discussion.
The
following is a summary of our contractual obligations and commitments at June 30, 2016 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due by Period
|
|
Contractual Obligations
|
|
Total
|
|
Less than
1 year
|
|
1-3 years
|
|
3-5 years
|
|
After
5 years
|
|
Total debt
|
|
$
|
133,813
|
|
$
|
127,759
|
|
$
|
4,427
|
|
$
|
984
|
|
$
|
643
|
|
Operating leases
|
|
$
|
17,050
|
|
$
|
6,651
|
|
$
|
6,864
|
|
$
|
2,450
|
|
$
|
1,085
|
|
Purchase obligations
|
|
$
|
25,360
|
|
$
|
24,730
|
|
$
|
630
|
|
$
|
|
|
$
|
|
|
Acquisition-related obligations
|
|
$
|
288,839
|
|
$
|
274,776
|
|
$
|
10,003
|
|
$
|
4,060
|
|
$
|
|
|
Defined benefit plan obligation
|
|
$
|
9,615
|
|
$
|
139
|
|
$
|
847
|
|
$
|
2,380
|
|
$
|
6,249
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total contractual obligations
|
|
$
|
474,677
|
|
$
|
434,055
|
|
$
|
22,771
|
|
$
|
9,874
|
|
$
|
7,977
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Commercial Commitmentsletters of credit
|
|
$
|
43,241
|
|
$
|
9,351
|
|
$
|
29,439
|
|
$
|
1,017
|
|
$
|
3,434
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
We
anticipate that cash generated from our operations, in addition to existing cash borrowing arrangements and future access to capital markets should be sufficient to meet our cash
requirements for the foreseeable future. However, our future capital requirements will depend on many factors, including future business acquisitions, capital expenditures, litigation, stock
repurchases and levels of research and development spending, among other factors. The adequacy of available funds will depend on many factors, including the success of our businesses in generating
cash, continued compliance with financial covenants contained in our credit facility and the health of capital markets in general, among other factors.
Cash Held by Foreign Subsidiaries
Our cash, cash equivalents, and investments totaled $104.4 million at June 30, 2016. Of this amount, approximately 96%
was held by our foreign subsidiaries and subject to repatriation tax considerations. These foreign funds were located primarily in Mexico, Malaysia and the United Kingdom, and to a lesser extent in
India, Singapore, Germany and China among others. We intend to permanently reinvest a significant portion of our earnings from foreign operations, and we currently do not anticipate that we will need
this cash in foreign countries to fund our U.S. operations. In the event that funds from foreign operations are needed to fund operations in the United States and if U.S. taxes have not been
previously provided on the related earnings, we would provide for and pay additional U.S. taxes at the time we change our intention with regard to the reinvestment of those earnings.
Stock Repurchase Program
Our Board of Directors authorized stock repurchase programs under which we may repurchase up to 5,500,000 shares of our Common Stock.
During fiscal 2016, we repurchased 1,201,402 shares under these programs. As of June 30, 2016, 1,063,158 shares were available for additional repurchase under these programs. Upon repurchase,
the shares are restored to the status of authorized but unissued shares and we record them as a reduction in the number of shares of Common Stock issued and outstanding in our consolidated financial
statements.
68
Table of Contents
Off Balance Sheet Arrangements
As of June 30, 2016, we had no off balance sheet arrangements, as defined in Item 303(a)(4) of Regulation S-K,
other than those previously disclosed.
New Accounting Pronouncements
For information with respect to new accounting pronouncements and the impact of these pronouncements on our consolidated financial
statements, see note 1 to the consolidated financial statements.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Market Risk
We are exposed to certain market risks, which are inherent in our financial instruments and arise from transactions entered into in the
normal course of business. We may enter into derivative financial instrument transactions in order to manage or reduce market risk in connection with specific foreign-currency-denominated
transactions. We do not enter into derivative financial instrument transactions for speculative purposes.
We
are subject to interest rate risk on our borrowings under our bank lines of credit. Consequently, our interest expense would fluctuate with changes in the general level of these
interest rates if we were to borrow any amounts under the credit facility.
Foreign Currency
Our international operations are subject to certain opportunities and risks, including foreign currency fluctuations and governmental
actions. We closely monitor our operations in each country and seek to adopt appropriate strategies that are responsive to changing economic and political environments, and to fluctuations in foreign
currencies. We conduct business in more than 20 countries. Due to our global operations, weaknesses in the currencies of some of these countries are often offset by strengths in others. Foreign
currency financial statements are translated into U.S. dollars at period-end rates, with the exception of revenues, costs and expenses, which are translated at average rates during the reporting
period. We include gains and losses resulting from foreign currency transactions in income, while we exclude those resulting from translation of financial statements from income and include them as a
component of accumulated other comprehensive income. Transaction gains and losses, which were included in our consolidated statement of operations, amounted to a gain (loss) of approximately $(1.8)
million, $2.1 million and $(0.8) million for the fiscal years ended June 30, 2014, 2015 and 2016, respectively. Furthermore, a 10% appreciation of the U.S. dollar relative to the local
currency exchange rates would have resulted in a net increase in our operating income of approximately $12.0 million in fiscal 2016. Conversely, a 10%
depreciation of the U.S. dollar relative to the local currency exchange rates would have resulted in a net decrease in our operating income of approximately $12.0 million in fiscal 2016.
Use of Derivatives
Our use of derivatives consists primarily of an interest swap agreement. As discussed in note 1 to the consolidated financial
statements, we had an interest rate swap of $5.2 million outstanding as of June 30, 2016.
Importance of International Markets
International markets provide us with significant growth opportunities. However, the following events, among others, could adversely
affect our financial results in subsequent periods: periodic economic downturns in different regions of the world, changes in trade policies or tariffs, civil or military conflict and other political
instability. We continue to perform ongoing credit evaluations of our customers' financial condition. We monitor economic and
69
Table of Contents
currency
conditions around the world to evaluate whether there may be any significant effect on our international sales in the future. Due to our overseas investments and the necessity of dealing with
local currencies in our foreign business transactions, we are at risk with respect to foreign currency fluctuations.
Inflation
We do not believe that inflation has had a material impact on our results of operations.
Interest Rate Risk
The principal maturity and estimated value of our long-term debt exposure as of June 30, 2016 were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maturity
|
|
|
|
|
|
|
|
2017
|
|
2018
|
|
2019
|
|
2020
|
|
2021
|
|
2022 and
thereafter
|
|
Total
|
|
Fair
Value
|
|
Secured long term loans and capital lease obligations
|
|
$
|
2,759
|
|
$
|
2,383
|
|
$
|
2,044
|
|
$
|
801
|
|
$
|
183
|
|
$
|
643
|
|
$
|
8,813
|
|
$
|
8,813
|
|
Average interest rate
|
|
|
2.1%
|
|
|
2.1%
|
|
|
2.1%
|
|
|
2.0%
|
|
|
1.9%
|
|
|
1.9%
|
|
|
2.1%
|
|
|
|
|
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
We make reference here to the Index to consolidated financial statements that appears on page F-1 of this report. The Report of
Independent Registered Public Accounting Firm from Moss Adams LLP, the Consolidated Financial Statements, the Notes to Consolidated Financial Statements,
Schedule IIValuation and Qualifying Accounts and Supplementary DataUnaudited Quarterly Results listed in the Index to Consolidated Financial Statements, which appear
beginning on page F-2 of this report, are incorporated by reference into this Item 8.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
ITEM 9A. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
As of June 30, 2016, the end of the period covered by this report, our management, including our Chief Executive Officer and our
Chief Financial Officer, reviewed and evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) of the Exchange Act). Based upon such
review and evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Annual Report on Form 10-K, our disclosure
controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the
time periods specified by the Securities and Exchange Commission and is accumulated and communicated to
management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Management's Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is
defined in Rule 13a-15(f) or 15d-15(f) of the Exchange Act) for the Company. Under the supervision and with the participation of management, including our Chief Executive Officer and Chief
Financial
70
Table of Contents
Officer,
we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework and criteria established in
Internal
ControlIntegrated Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013. Based on that evaluation, management
concluded that our internal control over financial reporting was effective as of June 30, 2016.
Moss
Adams LLP, an independent registered public accounting firm, has audited and reported on the consolidated financial statements of OSI Systems, Inc. and on the
effectiveness of our internal control over financial reporting. The report of Moss Adams LLP is contained in this annual report.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the fourth quarter of fiscal 2016 that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating our controls and procedures, management recognizes that any controls and procedures, no matter how well
designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship
of possible controls and procedures. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of
fraud, if any, within the Company have been detected.
ITEM 9B. OTHER INFORMATION
None.
71
Table of Contents